1 Title: The 2020 SARS-CoV-2 epidemic in England: key epidemiological drivers and impact

2 of interventions

3 Short title: Epidemiology of SARS-Cov-2 in England

One-sentence summary: We fit a mathematical model of SARS-CoV-2 transmission to
surveillance data from England, to estimate transmissibility, severity, and the impact of
interventions

7

Authors: Edward S. Knock^{1*}, Lilith K. Whittles^{1*}, John A. Lees^{1*}, Pablo N. Perez-Guzman^{1*},
Robert Verity¹, Richard G. FitzJohn¹, Katy AM Gaythorpe¹, Natsuko Imai¹, Wes Hinsley¹,
Lucy C. Okell¹, Alicia Rosello⁴, Nikolas Kantas⁵, Caroline E. Walters¹, Sangeeta Bhatia¹,
Oliver J Watson¹, Charlie Whittaker¹, Lorenzo Cattarino¹, Adhiratha Boonyasiri³, Bimandra
A. Djaafara¹, Keith Fraser¹, Han Fu¹, Haowei Wang¹, Xiaoyue Xi⁵, Christl A. Donnelly^{1,6}, Elita
Jauneikaite¹, Daniel J. Laydon¹, Peter J White^{1,2}, Azra C. Ghani¹, Neil M. Ferguson^{1^}, Anne
Cori^{1^}, Marc Baguelin^{1,4}

15

16 Affiliations: 1. MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel 17 Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial 18 College London; UK. 2. National Institute for Health Research Health Protection Research 19 Unit in Modelling and Health Economics, UK; 3. Department of Infectious Disease, School of 20 Public Health, Imperial College London; UK; 4. Department of Infectious Disease 21 Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene 22 and Tropical Medicine, London, UK; 5. Faculty of Natural Sciences, Department of 23 Mathematics, Imperial College London, UK; 6. Department of Statistics, University of Oxford, Oxford, UK 24 25

26 **Correspondence:** m.baguelin@imperial.ac.uk, neil.ferguson@imperial.ac.uk

27 *Equal contribution, ^Equal contribution

28 Main text: 3728 words

29 **Abstract** (125 words)

30 We fitted a model of SARS-CoV-2 transmission in care homes and the community 31 to regional surveillance data for England. Among control measures implemented, only 32 national lockdown brought the reproduction number below 1 consistently; introduced one 33 week earlier it could have reduced first wave deaths from 36,700 to 15,700 (95%Crl: 8,900-34 26,800). Improved clinical care reduced the infection fatality ratio from 1.25% (95%Crl: 35 1.18%–1.33%) to 0.77% (95%Crl: 0.71%–0.84%). The infection fatality ratio was higher 36 in the elderly residing in care homes (35.9%, 95%Crl: 29.1%–43.4%) than those residing in 37 the community (10.4%, 95%Crl: 9.1%–11.5%). England is still far from herd immunity, with 38 regional cumulative infection incidence to 1st December 2020 between 4.8% (95%Crl: 39 4.4%–5.1%) and 15.4% (95%Crl: 14.9%–15.9%) of the population.

40

41 **1** Introduction

England is among the countries worst-affected by the global pandemic of COVID-19, caused by the novel *Betacoronavirus* SARS-CoV-2. As of 2nd December 2020, over 51,000 deaths have been reported nationally, or 91 deaths per 100,000 people (*1*). The impact of the epidemic has varied across the country, with regional epidemics differing in their severity and timing. A key feature in all regions is the burden suffered by older adults living in care homes, where mortality has been high.

48

We use a mathematical model of SARS-CoV-2 transmission to reproduce the first two waves of the epidemic across England's seven NHS regions and assess the impact of interventions implemented by the UK government. We analyse the epidemic from importation of SARS-CoV-2 into each region to the 2nd December 2020: encompassing the first national lockdown from March – May, the interventions implemented as COVID-19 54 deaths increased again in the autumn, eventually leading to the second national lockdown in55 November.

56

57 We built an age-structured stochastic transmission model of SARS-CoV-2, representing care 58 homes, hospital clinical pathways and the wider community (Materials and Methods). We 59 developed a Bayesian evidence-synthesis approach to estimate model parameters and to 60 reconstruct regional epidemics using data from daily recorded deaths, PCR testing, hospital 61 admissions, hospital bed occupancy, individual patient outcomes, contact surveys, and 62 serological surveys. We evaluated temporal changes in transmission as new control 63 measures were implemented and then relaxed, and population immunity accrued. Inclusion 64 of serological data allowed us to robustly estimate region- and age-specific disease severity, 65 to compare severity in care home residents to elderly individuals in the community, and 66 estimate the total epidemic size, by calculating the proportion of individuals infected over 67 time in each region. Finally, we examined counterfactual epidemic scenarios, varying the 68 date and duration of the first national lockdown and the effectiveness of restricting care 69 home visits, to quantify the resulting impact on mortality.

70

Our analysis, which synthesises multiple data sources and parametrically accounts for their biases, provides a comprehensive overview of transmission, hospitalisation, and mortality patterns of SARS-CoV-2 in the first and second waves (up to 2nd December) in all regions of England. Our results provide crucial insights for controlling the epidemic in the future, emphasising the importance of acting fast to save lives.

76

77 2 Results

78 2.1 Epidemic trajectory

79

80 We used our evidence-synthesis approach, to infer the COVID-19 epidemic start date in 81 each NHS England region (Figure 1A), then reconstructed epidemic trajectories for 82 hospitalisations (Figure S7) and deaths in care homes and hospitals (Figure 1B-H). We 83 estimated the basic reproduction number, R_0 , defined as the expected number of onward 84 infections from an infectious individual in a fully susceptible population to be 2.9 (95% Crl: 2.8-3.1) nationally. Figure 1I shows how the effective reproduction number R_t^{eff} (the 85 86 expected number of onward infections from an individual infected at time t) changed in each 87 region over time, in relation to government control measures and accrual of population 88 immunity. The first COVID-19 death in England occurred on 5th March 2020 (2). Seven days later, in 89 90 response to the growing epidemic, the government began to introduce control measures, 91 initially requiring individuals with a dry persistent cough and/or fever to self-isolate (3). On 23rd March this escalated to a full national lockdown (4, 5). Irrespective of initial differences, 92 93 the level of transmission during lockdown was similar across all regions (Figure 1I). 94 consistent with mobility data showing movement during lockdown reduced to a consistent 95 level nationally (6).



Figure 1: Trajectory of the England COVID-19 epidemic. **A**, The inferred epidemic start date in each NHS England region. **B-H**, The model fit to reported daily deaths from COVID-19 in care homes and hospitals for each NHS England region. The points show the daily data, solid lines the median posterior and the shaded area shows the 95% Crl. **I**, The mean effective reproduction number within the general community (i.e. excluding care homes) in each region from March to December. Vertical lines and labels represent dates of key policy changes, defining the breaking points of the underlying piecewise linear transmission rate. Dashed horizontal line depicts reproduction number of 1.

105

The epidemic in London began 15 days before (95% Crl: 28 days before, 3 days after) the rest of the country (Figure 1A), meaning the lockdown occurred at a later stage of its epidemic. London experienced a mortality of 88.5 (95% Crl: 79.9–95.3) per 100,000 during the first wave, compared to the national average of 70.7 (95% Crl: 64.6–77.1), despite having a younger population and a smaller care home population than other regions (296 vs603 per 100,000 nationally).

A key feature of the first epidemic wave in England, in common with other European countries, was the high death toll within care homes, which accounted for 22.6% laboratoryconfirmed COVID-19 deaths in England as of 1st August 2020. Although community transmission rates fell during lockdown, transmission within care homes continued to rise, with infection risk peaking in care home residents, between 26th March in London and 12th April in North East and Yorkshire (Figure 2A). Deaths in care homes peaked on average 13 days later than hospital deaths (Figure 1B-H).



Figure 2: A, Inferred daily SARS-CoV-2 infections in England care home residents (right axis) and the
wider community (left axis). B-H, Comparison of modelled (shaded bands) and observed (solid line)
proportion of PCR tests that are positive, under pillar-2 testing (community swab testing for symptomatic
individuals) in >25 year olds. Shaded bands depict 95% Crl, 50% Crl and median model outputs.

124

The first lockdown in England continued until 11^{th} May, when people unable to work remotely were permitted to resume their jobs. Over the summer restrictions were successively eased, with non-essential shops, pubs and restaurants opening, followed by the government's 'Eat Out to Help Out' restaurant subsidy scheme in August (7). This led to a steady increase in transmission, with R_t^{eff} rising above 1 in all regions by mid-August (Figure 1I). 136 Increasing PCR test positivity marked the beginning of a second epidemic wave (Figure 2B-137 H, S6). The accompanying introduction of non-pharmaceutical interventions (NPIs) began 138 with the "Rule of Six" (limiting social gatherings to 6 persons maximum) on 14th September 139 (8), followed by the localised tiered restrictions on 14th October (9). These measures limited 140 transmission in most regions but were not sufficient to reduce R_t^{eff} below 1 (Figure 1I). 141 Consequently, on 31st October, the government announced a second national lockdown, 142 which lasted from 5th November to 1st December (*10*).

143

Restrictions during the second lockdown were less stringent than the first, with schools and some workplaces remaining open. This was reflected in R_t^{eff} estimates of 0.83 (95% CrI: 0.81–0.85) at the start of the second lockdown, compared to R_t^{eff} = 0.54 (95% CrI: 0.50– 0.59) at the start of the first. We estimate that without the population immunity accrued during the first wave, contact rates during the second lockdown would have resulted in a reproduction number of R_t = 0.95 (95% CrI: 0.93–0.98). Hence, population immunity helped to reduce transmission further below the critical threshold of R_t^{eff} = 1.

151

152 2.2 Severity and hospitalisation

153

154 COVID-19 manifests a broad spectrum of severity, from asymptomatic infection to life-155 threatening illness requiring intensive care. We estimated age-patterns of clinical 156 progression in people admitted to hospital using individual-level data from 17,702 patients admitted between 18th March and 31st May 2020 (inclusive) in the COVID-19 Hospitalisation 157 in England Surveillance System (CHESS, (11)) (Materials and Methods). We derived 158 159 estimates of the time spent in each stage of the hospital pathway (including general wards, 160 ICU and post-ICU stepdown care), as well as age-stratified probabilities of progression 161 through that pathway (Figure 3 and Figure S8). We accounted for differing length of stays 162 given different outcomes; there were marked differences in average length of ICU stay for

163 those who died in ICU, those who later died in stepdown care and those who were 164 discharged following stepdown care (Figure 3F). Among patients over 65, we found the 165 probability of admission to ICU decreased with increasing age. Severity of COVID-19 166 increases with age, but for older patients and those with most severe illness, the benefit of 167 ICU admission, ventilation and the corresponding prognosis may not be better than with 168 oxygen therapy in a general ward (12). Thus, older and more severely infected patients may 169 be directed to care on a general ward rather than admitted to ICU. 170 171 We used estimates of clinical progression to parametrise the transmission model, enabling 172 us to infer temporal and regional differences in disease severity, informed by local 173 demography, observed daily hospital admissions, bed occupancy and deaths. We measured 174 severity of disease by the infection fatality ratio (IFR) and the infection hospitalisation ratio

175 (IHR).

176

Patient progression in hospital





Figure 3: Age-dependent probabilities of progression through hospital pathways. A, Probability of
admission to ICU. B, Probability of death in a general ward. C, Probability of death in ICU. D,
Probability of death in stepdown care. E, Probability of death through all hospital pathways. Black
circles and vertical segments show posterior mean and 95% credible intervals of splines fitted to data,
blue circles and vertical segments show raw mean values and 95% confidence intervals (exact
binomial) for each 5-year age group. F, Average length of stay in each ward (posterior mean and 95%
credible intervals).

186

187 The severity of disease increased with age in all regions with the steepest increase above 188 65 years (Figure 4A-C), in line with observations worldwide (5). Regional estimates of age-189 aggregated disease severity depend on the population age distribution, which is similar in 190 most regions of the country, except London, where the median age is 34.6 years (vs 39.5 191 years nationally). At the start of the first wave, London experienced an IFR (respectively 192 IHR) of 0.91% (95% Crl: 0.82%–1.00%) (resp. 3.02%; 95% Crl: 2.82%–3.19%) compared to 193 the national average of 1.25% (95% Crl: 1.18%-1.33%) (resp. 3.52%; 95% Crl: 3.29%-194 3.72%) (Figure 4D-E).







Regional variation in the population age distribution did not fully account for differences in
severity, with London still experiencing lower mortality when stratified by age (Figure 4A-B).
The oldest age group (80+) in London had an IFR of 6.1% (95% CrI: 5.2%–6.8%) compared
to 12.7% (95% CrI: 10.8%–14.3%) in the North West.

211 We estimated temporal trends in the IFR for England, by weighting regional estimates by 212 incidence and population demographics. At the start of the first wave, the national IFR was 213 1.25% (95% Crl: 1.18%–1.33%) (Figure 4E), consistent with earlier reports from serology 214 data alone (13). The national IFR initially appeared to increase, as transmission widened 215 from London to regions with older populations and greater disease severity. Over the first 216 wave, the proportion of hospital admissions resulting in death decreased, due to 217 improvements in clinical management and alleviation of capacity constraints (14), leading to 218 a national IFR of 0.77% (95% CrI: 0.71%–0.84%) by the end of the first wave. The 219 magnitude of the relative reduction in IFR over time varied between regions, from 36.5% 220 (95% Crl: 26.5%–47.5%) in the North West to 64.6% (95% Crl: 58.6%–68.8%) in London. 221 222 The IFR was greater among care home residents (35.9%, 95% Crl: 29.1%–43.4%) than in 223 the 80+ in the community (10.4%, 95% Crl: 9.1%–11.5%, Figure 4C). Many care home 224 residents did not transfer into hospital, and instead died in the facilities where they lived, so 225 conversely the IHR was lower in care home residents (19.1%, 95% Crl: 11.5%-26.8%) than 226 in those aged 80+ in the community (51.1%, 95% Crl: 47.6%–54.3%). We present national 227 estimates of severity at the end of the second wave, stratified by age and care home 228 residency in Table S9.

229

230 2.3 Epidemic size

231

Data from repeated serological surveys of blood donors aged 15-65 informed our estimation of the total regional epidemic size (Figure 5A-G), accounting for imperfect sensitivity and specificity of serological tests (Materials and Methods) (*15*). The cumulative proportion of the population ever infected with SARS-CoV-2 ranged from 4.8% (95% Crl: 4.4%–5.1%) in the South West to 15.4% (95% Crl: 14.9%–15.9%) in London (Figure 5H). Predicted seropositivity was initially greater than cumulative incidence, due to imperfect test specificity.

238 The increase in seropositivity lagged cumulative infections by two weeks, reflecting the time



240



241

242 Figure 5: Cumulative incidence and seropositivity by region. A-G, Comparison of the estimated 243 proportion of the population testing seropositive with observations from serological surveys. Vertical 244 grey shaded bands show serological survey timings, black points the observed seroprevalence (bars: 245 95% exact confidence intervals), blue and purple lines show estimated proportion of the population 246 infected and seropositive respectively (shaded bands the 95% Crl, 50% Crl and median). H. 247 Comparison by region of the estimated cumulative attack rate in care home residents vs in the 80+ 248 age group in the community (median, 95% Crl). The final epidemic size in each England NHS region 249 I) in total and J) in care home residents. 250

Seropositivity notably declined following the first wave in some regions (Figure 5A-G). This may reflect antibody waning (*16*), or temporal trends in the composition of the surveyed population. Lockdown restrictions made attending blood donation centres difficult for all except key workers, who were more likely to have been infected (*17*), and may therefore be overrepresented in the sample of blood donors during the two lockdowns. The proportion of care home residents ever infected with SARS-CoV-2 was 13.7% (95% Crl: 10.7%–16.7%), much higher than the 4.2% (95% Crl: 4.0%–4.4%) estimated in >80-year olds living in the community. This difference was consistently observed across all regions (Figure 5H). Regional differences in care home attack rates mirrored the patterns seen in the general community, with regions with larger community epidemics also experiencing larger care home epidemics (Figure 5I,J).

- 262
- 263 2.4 Impact of non-pharmaceutical interventions (NPIs)

We explored counterfactual intervention scenarios and examined the potential impact on mortality of initiating the first national lockdown one week earlier or later; ending that lockdown two weeks earlier or later; and 50% more or less restricted care home visits throughout the epidemic (Figure 6).



Figure 6: Counterfactual analysis of the impact on mortality aggregated across NHS England regions of A, D, initiating lockdown one week earlier / later, B, E Relaxing lockdown two weeks earlier / later, and C, F 50% more / less restricted care home visits. Panels A, B, D and E all present counterfactual outcomes for daily deaths in England but have different yaxis scales to better highlight differences between the observed data and each alternative lockdown scenario.

276	The timing of the initial national lockdown was crucial in determining the eventual epidemic
277	size in England. Locking down a week earlier could have reduced the first wave death toll
278	(up to 1 st July 2020) from 36,700 to 15,700 (95% Crl: 8,900–26,800) while delaying
279	lockdown by a week would have increased the deaths to 102,600 (95% CrI: 66,400-
280	154,800) (Figure 6A, D). The impact varied by region, with regions with less established
281	epidemics at the time of the first lockdown more sensitive to the timing of the intervention
282	(Figure S10). Locking down a week later may have increased deaths, with large variability
283	by region, from 105% in London to 274% in the Midlands but with very large uncertainty
284	(Figure S9). Initiating a lockdown to interrupt the exponential growth phase of an epidemic
285	has a much greater impact on reducing total mortality than extending an existing lockdown.
286	Due to this asymmetry, relaxing the lockdown measures two weeks earlier (respectively
287	later), could have increased deaths by 9,300 (95% Crl: 700–17,000) (respectively prevented
288	9,800 (95% Crl: 7,400–12,100) deaths) prior to 2 nd December (Figure 6B, D).
289	
290	We also explored counterfactual scenarios varying the level of visit restriction in care homes
291	and estimated that reducing contact between the general population and care home

residents by 50% could have reduced care home deaths by 44% (95% Crl: 17%–64%)

293 (Figure 6C).

294

295 3 Discussion

296

297 We present a comprehensive overview of SARS-CoV-2 transmission, hospitalisation,

298 mortality and intervention impact in the first two epidemic waves across all regions of

299 England between March and December 2020. We successfully reproduce the transmission

300 dynamics of the two epidemic waves, in terms of cases, PCR prevalence, seroprevalence,

301 hospitalised cases (general wards and ICU), and deaths in hospitals and in care homes.

303 We estimate intense transmission in care homes even during the first national lockdown when R_t^{eff} in the community was well below one in all regions (Figure 2) (18–20). Combined 304 305 with our counterfactual analysis of restricting visits (Figure 6) this suggests that reducing 306 infection levels in care home residents is challenging. This highlights the difficulty of 307 protecting care home residents from COVID-19: due to the necessarily close contact 308 between staff and residents within a care home, once a care home outbreak has begun it is 309 very difficult to reduce transmission, which overrides any impact of reducing the number of 310 introductions (21, 22).

311

312 We find that, consistent with existing literature (23), disease severity increases with age. 313 Assessment of severity is complicated by the broad clinical spectrum of COVID-19 (24-26) 314 hence, recent published estimates are still based on data from early in the pandemic (27). 315 Here we provide updated severity estimates based on multiple contemporary data streams. 316 We estimate considerable regional heterogeneity in severity, broadly consistent in the 317 general population and in care homes for IFR and IHR. London experienced the lowest 318 severity even after adjusting for its younger population. The estimated two-fold reduction 319 over time in IFR (Figure 4) cannot be explained solely by the introduction of dexamethasone 320 which reduces mortality amongst ICU patients (28), but rather a combination of factors 321 including improvements in clinical management, greater experience in treating patients in 322 ICU, and alleviation of capacity constraints (14, 29).

323

Our analysis shows large regional variation in burden, especially in the first wave. This is likely due to the pattern of seeding and the timing of lockdown relative to how advanced each region's epidemic was (Figure 1A). Our counterfactual scenarios of initiating the first national lockdown one week earlier or later highlight the importance of early interventions to reduce overall mortality (Figure 6).

330 The extent and duration of infection-induced immunity to SARS-CoV-2 and its relationship to 331 seropositivity remains unclear. Related seasonal coronaviruses induce immunity that wanes 332 in one or two years (30), though antibody titres following SARS-CoV-1 infection appear to 333 decay more slowly (31). Our estimated cumulative incidence over time (Figure 5), strongly 334 supports the hypothesis that the epidemic decline after the first national lockdown was due 335 to NPIs, with immunity playing a minimal role (32). Population-level immunity was insufficient 336 to prevent a second wave of infection in any region (Figure 1), illustrated by the increase in 337 reported cases and deaths which prompted the second national lockdown (33).

338

339 With the authorisation of the first SARS-CoV-2 vaccines in December 2020, we are now 340 entering a new phase in the control of the COVID-19 pandemic. However, our estimates of 341 current population immunity are low, with regional cumulative attack rates ranging from 4.8% 342 to 15.4%, therefore any vaccination campaign will need to achieve high coverage and high 343 levels of protection in vaccinated individuals to allow NPIs to be lifted without a resurgence 344 of transmission. While vaccinating the most vulnerable age and risk groups will considerably 345 reduce the burden of COVID-19, a large proportion of younger age groups may also need to 346 be vaccinated to reach the immunity threshold for control. Our high estimates of 347 transmission in care homes imply that vaccine uptake there will need to be especially high, 348 particularly if vaccine efficacy is lower amongst older age groups.

349

We make a number of simplifying assumptions in our analysis. First, due to the compartmental nature of our model, we do not explicitly model individual care homes, rather the regional care home sector as a whole. However, as care home workers may work across multiple facilities leading to within and between care home transmission, we do not expect the simplification to substantially affect our conclusions. Similarly, we do not model individual households or transmission within and between them. When assessing the impact of NPIs

356 on transmission we therefore capture population averages, rather than the contribution of 357 household and non-household contacts. Second, hospital-acquired infections may have 358 contributed to overall transmission, especially around the peak of the epidemic, and to 359 persistence of infection in England over the summer months (34, 35). Our model does not 360 explicitly represent nosocomial transmission: therefore such effects will be encompassed within our regional R_t^{eff} estimates. Third, each data stream was subject to competing biases, 361 362 which we statistically accounted for as far as possible (supplement section 1.1.2). A key 363 strength of our evidence-synthesis approach is that we do not rely on any single data 364 source, combining multiple perspectives to provide a robust overall picture of the epidemic. 365 Finally, we model the epidemics in each NHS region in England independently without 366 accounting for spatial effects across regional boundaries, or spatial heterogeneity within 367 regions. This spatial scale was determined by the data and reflects limited movement 368 between regions due to travel restrictions but does allow for movement within regions. 369

370 Our analysis provides a comprehensive overview of transmission, hospitalisation, and 371 mortality patterns of COVID-19 in the first and second waves of the epidemic in all regions of 372 England, one of the countries worst-affected by the pandemic. Integration of multiple data 373 streams into a single cohesive modelling framework, enables us to disentangle transmission 374 and severity from features of the surveillance system and provide robust estimates of the 375 epidemiological characteristics of the COVID-19 epidemic in England. As nationwide 376 vaccination programmes are rolled out, our results will help to inform how NPIs are applied 377 in the future.

378

- 379 References
- 380
- 381 1. GOV.UK, Coronavirus (COVID-19) in the UK (2020), (available at
- 382 https://coronavirus.data.gov.uk/details/download).
- 383 2. E. Mahase, Covid-19: UK records first death, as world's cases exceed 100 000. *BMJ*.
 384 368 (2020), doi:10.1136/bmj.m943.
- 385 3. GOV.UK, Prime Minister's statement on coronavirus (COVID-19): 12 March 2020 386 GOV.UK, (available at https://www.gov.uk/government/speeches/pm-statement-on-
- 387 coronavirus-12-march-2020).
- 388 4. GOV.UK, Prime Minister's statement on coronavirus (COVID-19): 20 March 2020 -
- GOV.UK, (available at https://www.gov.uk/government/speeches/pm-statement-on coronavirus-20-march-2020).
- 391 5. GOV.UK, Prime Minister's statement on coronavirus (COVID-19): 22 March 2020 -

GOV.UK, (available at https://www.gov.uk/government/speeches/pm-statement-on coronavirus-22-march-2020).

- 394 6. B. Jeffrey, C. E. Walters, K. E. C. Ainslie, O. Eales, C. Ciavarella, S. Bhatia, S. Hayes,
- 395 M. Baguelin, A. Boonyasiri, N. F. Brazeau, G. Cuomo-Dannenburg, R. G. FitzJohn, K.
- 396 Gaythorpe, W. Green, N. Imai, T. A. Mellan, S. Mishra, P. Nouvellet, H. J. T. Unwin,
- 397 R. Verity, M. Vollmer, C. Whittaker, N. M. Ferguson, C. A. Donnelly, S. Riley,
- 398 Anonymised and aggregated crowd level mobility data from mobile phones suggests
- 399 that initial compliance with covid-19 social distancing interventions was high and
- 400 geographically consistent across the UK. *Wellcome Open Res.* **5**, 1–10 (2020).
- 401 7. HM Revenue & Customs, Get a discount with the Eat Out to Help Out Scheme.
- 402 *www.gov.uk* (2020).
- 403 8. GOV.UK, Rule of six comes into effect to tackle coronavirus GOV.UK, (available at
 404 https://www.gov.uk/government/news/rule-of-six-comes-into-effect-to-tackle405 coronavirus).

- 406 9. GOV.UK, Prime Minister announces new local COVID Alert Levels GOV.UK,
- 407 (available at https://www.gov.uk/government/news/prime-minister-announces-new408 local-covid-alert-levels).
- 409 10. GOV.UK, Prime Minister announces new national restrictions GOV.UK, (available at
- 410 https://www.gov.uk/government/news/prime-minister-announces-new-national-
- 411 restrictions).
- 412 11. NHS Digital, SGSS and CHESS data NHS Digital, (available at
- 413 https://digital.nhs.uk/about-nhs-digital/corporate-information-and-
- 414 documents/directions-and-data-provision-notices/data-provision-notices-dpns/sgss-
- 415 and-chess-data).
- 416 12. NHS, Overview | COVID-19 rapid guideline: critical care in adults | Guidance | NICE.
- 417 13. N. F. Brazeau, R. Verity, S. Jenks, H. Fu, C. Whittaker, P. Winskill, I. Dorigatti, P.
- 418 Walker, S. Riley, R. P. Schnekenberg, H. Hoeltgebaum, T. A. Mellan, S. Mishra, H. T.
- 419 Juliette Unwin, O. J. Watson, Z. M. Cucunubá, M. Baguelin, L. Whittles, S. Bhatt, A.
- 420 C. Ghani, N. M. Ferguson, L. C. Okell, Infection Fatality Ratio: Estimates from
 421 Seroprevalence, doi:10.25561/83545.
- 422 14. R. A. Armstrong, A. D. Kane, T. M. Cook, Outcomes from intensive care in patients
- 423 with COVID-19: a systematic review and meta-analysis of observational studies.
- 424 Anaesthesia. **75**, 1340–1349 (2020).
- 425 15. Public Health England, Sero-surveillance of COVID-19 GOV.UK, (available at
- 426 https://www.gov.uk/government/publications/national-covid-19-surveillance-
- 427 reports/sero-surveillance-of-covid-19).
- 428 16. F. J. Ibarrondo, J. A. Fulcher, D. Goodman-Meza, J. Elliott, C. Hofmann, M. A.
- 429 Hausner, K. G. Ferbas, N. H. Tobin, G. M. Aldrovandi, O. O. Yang, Rapid Decay of
- 430 Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N. Engl. J. Med.*, 1–2
- 431 (2020).
- 432 17. L. H. Nguyen, D. A. Drew, M. S. Graham, A. D. Joshi, C. G. Guo, W. Ma, R. S. Mehta,

433		E. T. Warner, D. R. Sikavi, C. H. Lo, S. Kwon, M. Song, L. A. Mucci, M. J. Stampfer,
434		W. C. Willett, A. H. Eliassen, J. E. Hart, J. E. Chavarro, J. W. Rich-Edwards, R.
435		Davies, J. Capdevila, K. A. Lee, M. N. Lochlainn, T. Varsavsky, C. H. Sudre, M. J.
436		Cardoso, J. Wolf, T. D. Spector, S. Ourselin, C. J. Steves, A. T. Chan, C. M. Albert, G.
437		Andreotti, B. Bala, B. A. Balasubramanian, L. E. Beane-Freeman, J. S. Brownstein, F.
438		J. Bruinsma, J. Coresh, R. Costa, A. N. Cowan, A. Deka, S. L. Deming-Halverson, M.
439		Elena Martinez, M. E. Ernst, J. C. Figueiredo, P. Fortuna, P. W. Franks, L. B.
440		Freeman, C. D. Gardner, I. M. Ghobrial, C. A. Haiman, J. E. Hall, J. H. Kang, B.
441		Kirpach, K. C. Koenen, L. D. Kubzansky, J. V Lacey, L. Le Marchand, X. Lin, P.
442		Lutsey, C. R. Marinac, M. E. Martinez, R. L. Milne, A. M. Murray, D. Nash, J. R.
443		Palmer, A. V Patel, E. Pierce, M. M. Robertson, L. Rosenberg, D. P. Sandler, S. H.
444		Schurman, K. Sewalk, S. V Sharma, C. J. Sidey-Gibbons, L. Slevin, J. W. Smoller, C.
445		J. Steves, M. I. Tiirikainen, S. T. Weiss, L. R. Wilkens, F. Zhang, Risk of COVID-19
446		among front-line health-care workers and the general community: a prospective
447		cohort study. Lancet Public Heal. 5, e475e483 (2020).
448	18.	GOV.UK, COVID-19: number of outbreaks in care homes - management information,
449		(available at https://www.gov.uk/government/statistical-data-sets/covid-19-number-of-
450		outbreaks-in-care-homes-management-information#history).
451	19.	S. N. Ladhani, J. Y. Chow, R. Janarthanan, J. Fok, E. Crawley-Boevey, A. Vusirikala,
452		E. Fernandez, M. S. Perez, S. Tang, K. Dun-Campbell, E. W. Evans, A. Bell, B. Patel,
453		Z. Amin-Chowdhury, F. Aiano, K. Paranthaman, T. Ma, M. Saavedra-Campos, R.
454		Myers, J. Ellis, A. Lackenby, R. Gopal, M. Patel, C. Brown, M. Chand, K. Brown, M. E.
455		Ramsay, S. Hopkins, N. Shetty, M. Zambon, Investigation of SARS-CoV-2 outbreaks
456		in six care homes in London, April 2020. EClinicalMedicine. 26, 100533 (2020).
457	20.	J. K. Burton, G. Bayne, C. Evans, F. Garbe, D. Gorman, N. Honhold, D. McCormick,
458		R. Othieno, J. E. Stevenson, S. Swietlik, K. E. Templeton, M. Tranter, L. Willocks, B.
459		Guthrie, Evolution and effects of COVID-19 outbreaks in care homes: a population

- 460 analysis in 189 care homes in one geographical region of the UK. *Lancet Heal.*461 *Longev.* 1, e21–e31 (2020).
- 462 21. L. J. Strausbaugh, S. R. Sukumar, C. L. Joseph, Infectious disease outbreaks in
 463 nursing homes: An unappreciated hazard for frail elderly persons. *Clin. Infect. Dis.* 36,
 464 870–876 (2003).
- 465 22. T. Inns, D. Wilson, P. Manley, J. P. Harris, S. J. O'Brien, R. Vivancos, What
 466 proportion of care home outbreaks are caused by norovirus? An analysis of viral
 467 causes of gastroenteritis outbreaks in care homes, North East England, 2016-2018.
 468 *BMC Infect. Dis.* 20, 2 (2019).
- 469 23. P. N. Perez-Guzman, A. Daunt, S. Mukherjee, P. Crook, R. Forlano, M. D. Kont, A.
- 470 Løchen, M. Vollmer, P. Middleton, R. Judge, C. Harlow, A. Soubieres, G. Cooke, P. J.
- 471 White, T. B. Hallett, P. Aylin, N. Ferguson, K. Hauck, M. R. Thursz, S. Nayagam,
- 472 Clinical characteristics and predictors of outcomes of hospitalized patients with
- 473 COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study. *Clin.*

474 Infect. Dis., 1–11 (2020).

- 475 24. A. B. Docherty, E. M. Harrison, C. A. Green, H. E. Hardwick, R. Pius, L. Norman, K.
- 476 A. Holden, J. M. Read, F. Dondelinger, G. Carson, L. Merson, J. Lee, D. Plotkin, L.
- 477 Sigfrid, S. Halpin, C. Jackson, C. Gamble, P. W. Horby, J. S. Nguyen-Van-Tam, A.
- 478 Ho, C. D. Russell, J. Dunning, P. J. M. Openshaw, J. K. Baillie, M. G. Semple,
- 479 Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO
- 480 Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ*. 369,
 481 1–12 (2020).
- 482 25. S. Tabata, K. Imai, S. Kawano, M. Ikeda, T. Kodama, K. Miyoshi, H. Obinata, S.
- 483 Mimura, T. Kodera, M. Kitagaki, M. Sato, S. Suzuki, T. Ito, Y. Uwabe, K. Tamura,
- 484 Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the
- 485 Diamond Princess cruise ship: a retrospective analysis. *Lancet Infect. Dis.* **20**, 1043–
 - 1050 (2020).

486

- 487 26. P. Vetter, D. L. Vu, A. G. L'Huillier, M. Schibler, L. Kaiser, F. Jacquerioz, Clinical
 488 features of covid-19. *BMJ*. 369, 1–2 (2020).
- 489 27. R. Verity, L. C. Okell, I. Dorigatti, P. Winskill, C. Whittaker, N. Imai, G. Cuomo-
- 490 Dannenburg, H. Thompson, P. G. T. Walker, H. Fu, A. Dighe, J. T. Griffin, M.
- 491 Baguelin, S. Bhatia, A. Boonyasiri, A. Cori, Z. Cucunubá, R. FitzJohn, K. Gaythorpe,
- 492 W. Green, A. Hamlet, W. Hinsley, D. Laydon, G. Nedjati-Gilani, S. Riley, S. van
- 493 Elsland, E. Volz, H. Wang, Y. Wang, X. Xi, C. A. Donnelly, A. C. Ghani, N. M.
- 494 Ferguson, Estimates of the severity of coronavirus disease 2019: a model-based
 495 analysis. *Lancet Infect. Dis.* (2020), doi:10.1016/S1473-3099(20)30243-7.
- 496 28. The RECOVERY Collaborative Group, Dexamethasone in Hospitalized Patients with
 497 Covid-19 Preliminary Report. *N. Engl. J. Med.*, 1–11 (2020).
- 498 29. L. I. Horwitz, S. A. Jones, R. J. Cerfolio, F. Francois, J. Greco, B. Rudy, C. M. Petrilli,
 499 Trends in COVID-19 Risk-Adjusted Mortality Rates. *J. Hosp. Med.* 23, 2020 (2020).
- 500 30. A. W. D. Edridge, J. Kaczorowska, A. C. R. Hoste, M. Bakker, M. Klein, K. Loens, M.
- 501 F. Jebbink, A. Matser, C. M. Kinsella, P. Rueda, M. leven, H. Goossens, M. Prins, P.
- 502 Sastre, M. Deijs, L. van der Hoek, Seasonal coronavirus protective immunity is short-
- 503 lasting. *Nat. Med.* (2020), doi:10.1038/s41591-020-1083-1.
- 31. S. M. Kissler, C. Tedijanto, E. Goldstein, Y. H. Grad, M. Lipsitch, Projecting the
- transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science*(80-.). 368, 860–868 (2020).
- 507 32. L. C. Okell, R. Verity, O. J. Watson, S. Mishra, P. Walker, C. Whittaker, A.
- 508 Katzourakis, C. A. Donnelly, S. Riley, A. C. Ghani, A. Gandy, S. Flaxman, N. M.
- 509 Ferguson, S. Bhatt, Correspondence Have deaths from COVID-19 in Europe
- 510 plateaued due to herd. *Lancet.* **395**, e110--e111 (2020).
- 511 33. Academy of Medical Science, Preparing for a challenging winter 2020/21, 79 (2020).
- 512 34. NHS England and NHS Improvement, "Hospital Onset Covid-19: IPC evidence from
 513 recent survey and next steps."

- 514 35. G. Iacobucci, Covid-19: Doctors sound alarm over hospital transmissions. *BMJ*. 369,
 515 m2013 (2020).
- 516 36. D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M.
- 517 Ipekci, G. Salanti, N. Low, Occurrence and transmission potential of asymptomatic
- 518 and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-
- 519 analysis. *PLoS Med.* **17**, e1003346 (2020).
- 520 37. S. Riley, C. E. Walters, H. Wang, O. Eales, K. E. C. Ainslie, C. Atchison, C. Fronterre,
- 521 P. J. Diggle, D. Ashby, C. A. Donnelly, G. Cooke, W. Barclay, H. Ward, A. Darzi, P.
- 522 Elliott, *medRxiv*, in press, doi:10.1101/2020.12.15.20248244.
- 523 38. Office for National Statistics, Office for National Statistics, (available at
- 524 https://www.ons.gov.uk/).
- 525 39. Care Quality Commission, [ARCHIVED CONTENT] UK Government Web Archive -
- 526 The National Archives, (available at
- 527 https://webarchive.nationalarchives.gov.uk/20200605160439/https://www.cqc.org.uk/fi
- 528 les/cqc-care-directory-filters-1-june-2020).
- 529 40. GOV.UK, "Care Homes Analysis Background" (2020).
- 530 41. Age UK, Later Life in the United Kingdom 2019, (available at
- 531 https://www.ageuk.org.uk/globalassets/age-uk/documents/reports-and-
- 532 publications/later_life_uk_factsheet.pdf).
- 533 42. J. Mossong, N. Hens, M. Jit, P. Beutels, K. Auranen, R. Mikolajczyk, M. Massari, S.
- 534 Salmaso, G. S. Tomba, J. Wallinga, J. Heijne, M. Sadkowska-Todys, M. Rosinska, W.
- J. Edmunds, Social contacts and mixing patterns relevant to the spread of infectious
 diseases. *PLoS Med.* 5, 381–391 (2008).
- 43. S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith, A. S. Azman,
- 538 N. G. Reich, J. Lessler, The incubation period of coronavirus disease 2019 (CoVID-
- 539 19) from publicly reported confirmed cases: Estimation and application. *Ann. Intern.*
- 540 *Med.* **172**, 577–582 (2020).

541 44. Q. Bi, Y. Wu, S. Mei, C. Ye, X. Zou, Z. Zhang, X. Liu, L. Wei, S. A. Truelove, T. Zhang, W. Gao, C. Cheng, X. Tang, X. Wu, Y. Wu, B. Sun, S. Huang, Y. Sun, J. 542 Zhang, T. Ma, J. Lessler, T. Feng, Epidemiology and transmission of COVID-19 in 543 544 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis (2020), doi:10.1016/s1473-3099(20)30287-5. 545 546 45. M. Bernabeu-Wittel, J. E. Ternero-Vega, P. Díaz-Jiménez, C. Conde-Guzmán, M. D. Nieto-Martín, L. Moreno-Gaviño, J. Delgado-Cuesta, M. Rincón-Gómez, L. Giménez-547 548 Miranda, . D Navarro-Amuedo, M. M. Muñoz-García, S. Calzón-Fernández, M. Ollero-549 Baturone, Death risk stratification in elderly patients with covid-19. A comparative 550 cohort study in nursing homes outbreaks. Arch. Gerontol. Geriatr. 91, 104240 (2020). 551 46. S. Omar, C. Bartz, S. Becker, S. Basenach, S. Pfeifer, C. Trapp, H. Hamm, H. C. 552 Schlichting, M. Friederichs, U. Koch, C. Jestrabek, E. Hilger, M. Vogt, K. Jahn, S. 553 Chen, T. Barnighausen, P. Zanger, Duration of SARS-CoV-2 RNA detection in 554 COVID-19 patients in home isolation, Rhineland-Palatinate, Germany, 2020 - an interval-censored survival analysis. Eurosurveillance. 25, 1-8 (2020). 555 556 47. B. Benny, G. Amandine, P. Kc, H. Sarah, M. Abby, C. Caitlin, S. Van, L.-S. James, O. 557 Affiliations, Quantifying antibody kinetics and RNA shedding during early-phase 558 SARS-CoV-2 infection, doi:10.1101/2020.05.15.20103275. 559 S. Funk, Socialmixr: Social Mixing Matrices for Infectious Disease Modelling (2018). 48. 560 GOV.UK. Prime Minister's statement on coronavirus (COVID-19): 25 March 2020 -49. 561 GOV.UK, (available at https://www.gov.uk/government/speeches/pm-statement-on-562 coronavirus-25-march-2020). GOV.UK, Prime Minister's statement on coronavirus (COVID-19): 11 May 2020 -563 50. 564 GOV.UK, (available at https://www.gov.uk/government/speeches/pm-statement-on-565 coronavirus-11-may-2020). 566 51. GOV.UK, Prime Minister sets out timeline for retail to reopen in June - GOV.UK,

567 (available at https://www.gov.uk/government/news/prime-minister-sets-out-timeline-

568 for-retail-to-reopen-in-june).

- 569 52. GOV.UK, Pubs, restaurants and hairdressers to reopen from 4 July GOV.UK,
- 570 (available at https://www.gov.uk/government/news/pubs-restaurants-and-
- 571 hairdressers-to-reopen-from-4-july).
- 572 53. GOV.UK, Eat Out to Help Out launches today with government paying half on
- 573 restaurant bills GOV.UK, (available at https://www.gov.uk/government/news/eat-out-
- 574 to-help-out-launches-today-with-government-paying-half-on-restaurant-bills).
- 575 54. GOV.UK, Schools and colleges to reopen in full in September GOV.UK, (available at
- 576 https://www.gov.uk/government/news/schools-and-colleges-to-reopen-in-full-in-
- 577 september).
- 578 55. O. Diekmann, J. A. P. Heesterbeek, J. A. J. Metz, On the definition and the
- 579 computation of the basic reproduction ratio R0 in models for infectious diseases in

580 heterogeneous populations. J. Math. Biol. 28, 365–382 (1990).

- 58. D. T. Gillespie, Approximate accelerated stochastic simulation of chemically reacting
 systems. *J. Chem. Phys.* **115**, 1716–1733 (2001).
- 583 57. Department of Health and Social Care, COVID-19 testing data: methodology note.
 584 *www.gov.uk* (2020).
- 585 58. I. M. C. Martin, C. A. Ison, D. M. Aanensen, K. A. Fenton, B. G. Spratt, Rapid
- 586 Sequence-Based Identification of Gonococcal Transmission Clusters in a Large

587 Metropolitan Area. J. Infect. Dis. **189**, 1497–1505 (2004).

- 588 59. P. Del Moral, A. Doucet, A. Jasra, Sequential Monte Carlo samplers. *J. R. Stat. Soc.*589 Ser. B Stat. Methodol. 68, 411–436 (2006).
- 590 60. C. Andrieu, A. Doucet, R. Holenstein, Particle Markov chain Monte Carlo methods. J.
- 591 *R. Stat. Soc. Ser. B Stat. Methodol.* **72**, 269–342 (2010).
- 592 61. N. J. Gordon, D. J. Salmond, A. F. M. Smith, Novel approach to nonlinear/non-
- 593 gaussian Bayesian state estimation. *IEE Proceedings, Part F Radar Signal Process.*
- **140**, 107–113 (1993).

- 595 62. M. Baguelin, E. Knock, L. K. Whittles, R. FitzJohn, J. Lees, sircovid (2020).
- 596 63. E. S. Knock, L. K. Whittles, P. N. Perez-Guzman, S. Bhatia, F. Guntoro, O. J. Watson,
- 597 C. Whittaker, N. M. Ferguson, A. Cori, M. Baguelin, R. G. FitzJohn, J. A. Lees,
- 598 Reproducible parallel inference and simulation of stochastic state space models using 599 odin, dust, and mcstate. *Wellcome Open Res.* **5**, 288 (2020).
- 600 64. M. Plummer, N. Best, K. Cowles, K. Vines, CODA: Convergence Diagnosis and
 601 Output Analysis for MCMC. *R News*. 6, 7–11 (2006).
- 602 65. A. Gelman, D. B. Rubin, Inference from iterative simulation using multiple sequences.
 603 *Stat. Sci.* 7, 457–472 (1992).
- 604 66. R. Verity, R. FitzJohn, mrc-ide/markovid at version1.5, (available at

605 https://github.com/mrc-ide/markovid/tree/version1.5).

- 606 67. C. I. Jarvis, K. Van Zandvoort, A. Gimma, K. Prem, M. Auzenbergs, K. O'Reilly, G.
- 607 Medley, J. C. Emery, R. M. G. J. Houben, N. Davies, E. S. Nightingale, S. Flasche, T.
- Jombart, J. Hellewell, S. Abbott, J. D. Munday, N. I. Bosse, S. Funk, F. Sun, A. Endo,
- A. Rosello, S. R. Procter, A. J. Kucharski, T. W. Russell, G. Knight, H. Gibbs, Q.
- 610 Leclerc, B. J. Quilty, C. Diamond, Y. Liu, M. Jit, S. Clifford, C. A. B. Pearson, R. M.
- 611 Eggo, A. K. Deol, P. Klepac, G. J. Rubin, W. J. Edmunds, Quantifying the impact of
- 612 physical distance measures on the transmission of COVID-19 in the UK. *BMC Med.*

613 **18**, 1–10 (2020).

- 614 68. E. Lavezzo, E. Franchin, C. Ciavarella, G. Cuomo-Dannenburg, L. Barzon, C. Del
- 615 Vecchio, L. Rossi, R. Manganelli, A. Loregian, N. Navarin, D. Abate, M. Sciro, S.
- 616 Merigliano, E. De Canale, M. C. Vanuzzo, V. Besutti, F. Saluzzo, F. Onelia, M.
- 617 Pacenti, S. G. Parisi, G. Carretta, D. Donato, L. Flor, S. Cocchio, G. Masi, A. Sperduti,
- L. Cattarino, R. Salvador, M. Nicoletti, F. Caldart, G. Castelli, E. Nieddu, B. Labella, L.
- 619 Fava, M. Drigo, K. A. M. Gaythorpe, K. E. C. Ainslie, M. Baguelin, S. Bhatt, A.
- 620 Boonyasiri, O. Boyd, L. Cattarino, C. Ciavarella, H. L. Coupland, Z. Cucunubá, G.
- 621 Cuomo-Dannenburg, B. A. Djafaara, C. A. Donnelly, I. Dorigatti, S. L. van Elsland, R.

622		FitzJohn, S. Flaxman, K. A. M. Gaythorpe, W. D. Green, T. Hallett, A. Hamlet, D.		
623		Haw, N. Imai, B. Jeffrey, E. Knock, D. J. Laydon, T. Mellan, S. Mishra, G. Nedjati-		
624		Gilani, P. Nouvellet, L. C. Okell, K. V. Parag, S. Riley, H. A. Thompson, H. J. T.		
625		Unwin, R. Verity, M. A. C. Vollmer, P. G. T. Walker, C. E. Walters, H. Wang, Y. Wang,		
626		O. J. Watson, C. Whittaker, L. K. Whittles, X. Xi, N. M. Ferguson, A. R. Brazzale, S.		
627		Toppo, M. Trevisan, V. Baldo, C. A. Donnelly, N. M. Ferguson, I. Dorigatti, A. Crisanti,		
628		Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. Nature		
629		(2020), doi:10.1038/s41586-020-2488-1.		
630	69.	NHS England and NHS Improvement, Statistics » COVID-19 Hospital Activity,		
631		(available at https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-		
632		hospital-activity/).		
633				
634				
635	Ackn	owledgements		
636	We th	ank all the colleagues at Public Health England (PHE) and frontline health		
637	professionals who have driven and continue to drive the daily response to the epidemic, but			
638	also for providing the necessary data to inform this study. This work would not have been			
639	possil	ble without their dedication and expertise. The use of pillar 2 PCR testing data was		
640	made possible thanks to PHE colleagues and we extend our thanks to Dr Nick Gent and Dr			
641	André Charlett for facilitation and their insights into these data. The use of serological data			
642	was made possible by colleagues at PHE Porton Down, Colindale, and the NHS Blood			
643	Transfusion Service. We are particularly grateful to Dr Gayatri Amirthalingam and Prof Nick			
644	Andrews for helpful discussions around these data. We also thank the entire Imperial			
645	College London Covid-19 Response Team for their support and feedback throughout. This			
646	work was supported by the NIHR HPRU in Modelling and Health Economics, a partnership			
647	betwe	en PHE, Imperial College London and LSHTM (grant code NIHR200908). We		
648	ackno	wledge funding from the MRC Centre for Global Infectious Disease Analysis		

649	(reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and
650	the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO
651	Concordat agreement and is also part of the EDCTP2 programme supported by the
652	European Union.
653	
654	Disclaimer
655	The views expressed are those of the authors and not necessarily those of the United
656	Kingdom (UK) Department of Health and Social Care, the National Health Service, the
657	National Institute for Health Research (NIHR), Public Health England (PHE), UK MRC, UKRI
658	or European Union.
659	
660	List of Supplementary Materials
661	Supplementary materials (Materials and Methods, Supplementary Results)
662	Supplementary data files: data_rtm.csv, data_serology.csv, support_progression.csv,
663	support_severity.csv
664	
665	Data availability statement
666	All code and de-identified regionally aggregated data (see supplementary materials for full
667	details) required to reproduce this analysis are available at https://github.com/mrc-
668	ide/sarscov2-transmission-england (https://zenodo.org/record/4384864)

Supplementary Materials

1 2

3 Table of Contents

4	1 N	Mat	erials and Methods	2
5	1.1		Data sources	2
6	1	.1.1	Hospital admissions and bed occupancy	2
7	1	.1.2	Deaths	2
8	1	.1.3	Pillar 2 testing	3
9	1	.1.4	Serology surveys	3
10	1	.1.5	REACT-1 prevalence survey	3
11	1	.1.6	Summary of the data used for calibration	3
12	1	.1.7	Other data sources	4
13	1.2		Evidence synthesis	4
14	1.3		Model description	6
15	1	.3.1	Stratification of population into groups	6
16	1	.3.2	Progression of infection and hospitalisation	6
17	1	.3.3	Progression of infection and hospitalisation	8
18	1	3.4	Age-varying and time-varying infection progression probabilities	11
19	1.4		Reproduction number <i>Rt</i> and effective reproduction number <i>Rteff</i>	12
20	1.5		Infection severity	12
21	1.6		Compartmental model equations	13
22	1.7		Observation process	18
23	1	.7.1	Notation for distributions used in this section	19
24	1	.7.2	Hospital admissions and new diagnoses in hospital	19
25	1	.7.3	Hospital bed occupancy by confirmed COVID-19 cases	19
26	1	7.4	Hospital and care homes COVID-19 deaths	20
27	1	.7.5	Serosurveys	20
28	1	.7.6	PCR testing	21
29	1.8		Bayesian inference and model fitting	22
30	1.9		Prior distributions and parameter calibration	24
31	1	.9.1	Risk of hospital admission	24
32	1	.9.2	Severity and hospital progression	25
33	1	.9.3	Serosurveys	29
34	1	9.4	PCR positivity	29
35	1	9.5	Local start date of the epidemic	29
36	1	9.6	Time-varying transmission rates	30
37	1	9.7	Transmission within care homes	
38	1	9.8	Parameters relating to Pillar 2 testing	30
39	2 S	Supp	plementary Results	35
40	2.1		Model fitting and validation	35
41	2.2		Severity estimates	36
42	2.3		Supplementary counterfactual analysis	37

45

46 **1 Materials and Methods**

47 Understanding the transmission of SARS-CoV-2 is challenging. The available data are 48 subject to competing biases, such as dependence on case definition for testing and 49 reporting, as well as being influenced by capacity and logistical constraints. These factors 50 are further complicated by the nature of SARS-CoV-2 transmission, whereby a substantial 51 proportion of infected individuals develop very mild symptoms, or remain asymptomatic, but 52 are nonetheless able to infect others (1). In this section, we describe the data used in our 53 analyses, give details on the dynamic transmission model, and present the methods used for 54 fitting the model to the various data sources, accounting for the inherent biases in those 55 data.

56

57 1.1 Data sources

58 Here we detail the datasets used to calibrate the model to the regional epidemics. We fitted 59 our model to time series data spanning 16th March 2020 to 2nd December 2020 (inclusive), 60 using the data available to us on 14th December 2020, by which point the effect of

using the data available to us on 14th December 2020, byremaining reporting lags would be minimal.

62

63

1.1.1 Hospital admissions and bed occupancy

We use healthcare data for each NHS region from the UK Government Dashboard
(supplementary data files: *data_rtm.csv*, columns: *phe_admissions*, *phe_occupied*, *phe_patients*) (2).

67 For admissions data, we use the daily number of confirmed COVID-19 patients admitted to

68 hospital, which includes people admitted to hospital who tested positive for COVID-19 in the

69 14 days prior to admission and inpatients who tested positive in hospital after admission,

with the latter being reported as admitted on the day prior to their diagnosis.

- For ICU bed occupancy, we use the daily number of (confirmed) COVID-19 patients in bedswhich are capable of delivering mechanical ventilation.
- For the occupancy in general (i.e. non-ICU) hospital beds, we use the daily number ofconfirmed COVID-19 patients in hospital beds with ICU occupancy subtracted.
- 75 1.1.2 Deaths

76 We use the number of deaths by date of death for people who had a positive COVID-19 test 77 result and died within 28 days of their first positive test provided Public Health England. 78 These can be found on (2). We also use the number among these deaths occurring in 79 hospital (as reported by NHS England) and consider the remainder to have occurred in care 80 homes. While non-hospital deaths may include deaths in other settings, such as in private 81 residences, comparison with ONS data suggests that care home deaths from COVID-19 82 may also have been under-reported. As such we consider non-hospital deaths to be an 83 appropriate proxy for care home deaths, and do not expect the margin for under or over-84 ascertainment to affect our conclusions. These data were provided by PHE and the data we 85 have been using is provided as a supplementary file (supplementary data file: data rtm.csv,

87 1.1.3 Pillar 2 testing

We use pillar 2 testing data (see supplementary data files), which covers PCR testing for the
general population (as compared with pillar 1 testing, which mainly occurred in hospitals).
Since such testing was not available to the whole population for much of the spring wave of
the pandemic, we only use this data from June 1st onwards.

92 We use the daily number of positives and negative tests by specimen date. Each individual 93 who tested positive was only counted once in the number of positives, on the specimen date 94 of their first positive test. Multiple negatives were allowed per individual, but the negatives of 95 all individuals who ever tested positive had been removed. We only consider PCR tests and 96 thus exclude lateral flow tests, which have been introduced recently in trials of population 97 mass testing. We also only use pillar 2 data for those aged 25 or over, to avoid bias resulting 98 from increased testing of university students around the reopening of universities (supplementary data file: data rtm.csv, columns: pillar2_negatives_non_lft_over25, 99 100 pillar2 positives over25).

101 1.1.4 Serology surveys

Serological survey data come from antibody testing by Public Health England of samples
 from healthy adult blood donors, supplied by NHS Blood and Transplant (NHSBT)

- 104 (supplementary data file: *data serology.csv*).
- 105 *1.1.5 REACT-1 prevalence survey*

We use the daily number of positives and negatives by specimen date from the first 7 rounds of the REACT-1 (Real-time Assessment of Community Transmission) infection prevalence survey (supplementary data file: *data_rtm.csv*, columns: *react_positive, react_samples*) (3). Note that results published in REACT preprints use data aggregated using the administrative regions of England, whereas for the purposes of this study the data has been aggregated using NHS regions. Additionally, small changes can occur in the aggregated datasets that were published in real time because of participant withdrawals and additional data cleaning.

- 113 1.1.6 Summary of the data used for calibration
- 114 Table S 1 details the datasets used to calibrate the model to the regional epidemics.
- 115 Table S 1: Data sources and definitions.

Data type	Description	Source	Reference
Hospital deaths	Daily number of COVID-19 deaths reported by NHS England within 28 days of a positive result	PHE	See data supplement. These data underlie what is released on (2)
Care home deaths	Daily number of COVID-19 deaths not reported by NHS England within 28 days of a positive result	PHE	See data supplement. These data underlie what is released on (2)
ICU occupancy	Daily number of confirmed COVID-19 patients in ICU	Gov.uk Dashboard	(2)
General bed occupancy	Daily number of confirmed COVID-19 patients in non-ICU beds	Gov.uk Dashboard	(2)
Admissions	Daily number of confirmed COVID-19 patients admitted to hospital	Gov.uk Dashboard	(2)
Pillar 2 testing	Daily number of positive and negative PCR test results	PHE	See data supplement. These data underlie what is released on (2)
REACT-1 testing	Daily number of positive and negative PCR test results	REACT	(3)

Serology	Serology survey conducted on blood donors aged 15-65	PHE	See data supplement, these data are collected as part of (4)
Patient progression in	Number of hospital admissions going	CHESS	(5)
hospital	down each treatment route (e.g. ICU, stepdown care) and length of stay in each ward.		

116 1.1.7 Other data sources

117 1.1.7.1 Patient progression in hospital

The COVID-19 Hospitalisation in England Surveillance System (CHESS) data consists of a line list of daily individual patient-level data on COVID-19 infection in persons requiring hospitalisation, including demographic and clinical information on severity and outcomes. We use the individual dates of progression through hospital wards, from admission to eventual death or discharge, to produce age-stratified estimates of hospital progression parameters to be passed to the wider transmission model (see Section 1.9.2 and

124 (supplementary data file: *support_progression.csv, support_severity.csv*).

125 1.1.7.2 Demographic data

We use data from the Office for National Statistics (ONS (6)) to get the number of individuals in each of the 17 age-groups, i.e. 16 five-year age bands (0-4, 5-9, ..., 75-79) and an 80+

128 group. We get the number of care-home beds in England from (7) giving us the number of 129 care-home beds for each NHS regions. We then got an estimate of the total population of

130 care-home residents in the UK from (8) that we scaled down to the England population size,

131 combined with the estimate of the total number of beds in England, we derived a value of the

total occupancy of care-homes of 74.2%. We assumed that the occupancy is the same in all

the NHS regions. Care-home residents are subtracted from the 4 oldest age group (5% from

age 65-69, 5% age 70-74, 15% age 75-79 and 75% age 80+ (9)). We then assume a 1:1
ratio of care-home residents to care-home workers and assume that the care-home workers

136 population is homogeneously distributed among the 25-65 population in the region.

137 The contact matrix between the 17 age-groups is based on the POLYMOD contact survey.

- 138 See parameterisation for more details (10).
- 139

140 **1.2 Evidence synthesis**

141 Figure S 1 shows the functional relationships between data sources, modelled outputs and

142 parameters in our study.



144 Figure S 1: Graph showing the functional relationships between data sources (rectangles), modelled outputs (ovals) and parameters (hexagons).

145 **1.3 Model description**

We developed a stochastic compartmental transmission-dynamic model incorporating
hospital care pathways to reconstruct the course of the COVID-19 epidemic in the seven
NHS regions of England (Figure S 2). All analyses were done by regions, and then
aggregated somehow if needed (e.g. for national IFR, or cumulative incidence). In the
following description we do not mention any index denoting the region and thus all notations
refer to the same NHS region.

152 1.3.1 Stratification of population into groups

153 We divided each regional population into 19 strata, denoted by the superscript i, 17 strata 154 representing age groups within the general population, and two separate risk groups 155 comprising care home workers (CHW) and care home residents (CHR). The 17 age groups consisted of 16 five-year age bands (0-4, 5-9, ..., 75-79) and an 80+ group. The total size of 156 157 the care home worker and resident groups were calculated assuming that 74.2% of available 158 care home beds are occupied and there is a 1:1 carer to resident ratio (11). The care home 159 workers were then split equally between all 8 age categories in the range 25 – 64-year-old 160 and removed from the corresponding age categories in the general population. Despite the 161 care-home workers being removed from all age categories in the range 25 – 64-year-old, 162 they care-home workers are assumed to constitute one single group in our model for 163 simplicity. The care home residents were drawn from the 65+ year old general population, such that 5% were aged 65-69, 5% aged 70-74, 15% aged 75-79 and 75% aged 80+ (9) and 164 165 similarly removed from the corresponding age groups in the general population. Again, similarly to care-home workers they do constitute a single group in our model. We thus 166 167 do not capture specific transmission dynamics within each care home, but rather an average 168 mixing between residents and workers in the regional care home sector as a whole. 169

170 1.3.2 Progression of infection and hospitalisation

171 Prior to the importation of COVID-19, all individuals were assumed equally susceptible to 172 infection (S). Upon infection, individuals pass through a latent period (E) before becoming 173 infectious. A proportion (p_c) of infectious individuals develop symptoms (I_c) while the rest 174 remain asymptomatic (I_A) . All asymptomatic individuals are assumed to recover naturally. Those with symptoms may also recover naturally (R), however a proportion (p_H^i) , age/care 175 176 home-dependant as indicated by the *i* superscript) develop severe disease requiring hospitalisation. Of these, a proportion $(p_{G_D}^i)$ die at home without receiving hospital care. In 177 practice this proportion is set to zero except among care home residents. Of the patients 178 179 who are admitted to hospital, a proportion $(p^*(t))$ have their COVID-19 diagnoses confirmed 180 prior to admission, while the remainder may be diagnosed during their inpatient stay. All 181 hospital compartments are divided between suspected (but not yet confirmed) and 182 confirmed diagnoses (indicated by superscript *). A proportion $(p_{ICU}^{i}(t))$ of new hospital admissions are triaged (ICU_{pre}) before admission to the intensive care unit (ICU), where a 183 fraction $(p_{ICU_D}^i(t))$ die; those who do not die get out of ICU to a ward (W) where a proportion 184 $(p_{W_D}^i(t))$ die, while the remainder recover, following an inpatient care stepdown period. 185 Inpatients not triaged to the ICU are assigned to general hospital beds (H), where a 186 187 proportion $(p_{H_{D}}^{i}(t))$ die, while the remainder recover. Recovered individuals are assumed to 188 be immune to reinfection for at least the duration of the simulation.

189 In addition, there are two parallel flows which we use for fitting to testing data: (i) for PCR 190 positivity and (ii) for seropositivity. Upon infection, an individual enters the PCR flow in a pre-191 positivity compartment ($T_{PCR_{pre}}$) before moving into the PCR positivity compartment ($T_{PCR_{pos}}$) and then ultimately into the PCR negativity compartment $(T_{PCR_{neg}})$. Meanwhile, individuals move into the seropositivity flow upon becoming infectious, entering first into a preseropositivity compartment $(T_{sero_{pre}})$. A proportion of individuals $(p_{sero_{pos}})$ then seroconvert and move into the seropositivity compartment $(T_{sero_{pos}})$, while the remainder move into the seronegativity compartment $(T_{sero_{neg}})$.

197 We calibrated the duration distributions for each hospital compartment, and the age-stratified

198 probabilities of moving between compartments, using the analysis of individual-level patient

data (presented below in Section 1.9.2). The required Erlang distributional form was

- achieved within the constraints of the modelling framework by splitting each model
- 201 compartment into k sequential sub-compartments (Table S 2).
- 202



Figure S 2: Model structure flow diagram with rates of transition between infection states. Variable
 names defined in text.

207Table S 2: Description of model compartments and distribution of time spent in each. For each named208compartment, we give the associated duration. Due to the Markovian structure these are model209Second and the second duration. Due to the Markovian structure these are model

209 Erlang-like distributions with k_j the number of exponential-like compartments and γ_j the rate of the

210 exponential-like compartment. $\mathbb{E}[\tau_j]$ gives the mean duration in days spent in the corresponding

211 compartment. The structure and duration of each stage was assumed to be the same for unconfirmed 212 and confirmed cases in hospital (see Figure S2). For length of stays related to hospital pathways,

213 more detail is given in section 1.9.2.

Compartment	Description	Duration		(days)	Source
		$\tau_j \sim \text{Erlar}$	$\log(k_j, \gamma_j)$	$\mathbb{E}[\tau_j] = k_j / \gamma_j$	
j		k_j	γ_j	(95% CI)	
S	Susceptible to infection		Determin	ed by transmission	dynamics
Ε	Latent infection	2	0.44	4.6 (0.6, 12.8)	Lauer et al.(12)
I_A	Asymptomatic infection	1	0.48	2.1 (0.1, 7.7)	<i>Bi et al.</i> (13)
Ic	Symptomatic infection	1	0.25	4.0 (0.1, 14.8)	Docherty et al.(14)
G _D	Severe illness leading to death in the general population	2	0.40	5.0	Bernabeu-Wittel et al. (15)
H _R	Hospitalised on general ward leading to recovery	1	0.09	10.7 (0.3, 39.4)	Fitted to CHESS
H_D	Hospitalised on general ward leading to death	2	0.19	10.3 (1.3, 28.8)	Fitted to CHESS
ICU _{pre}	Triage to ICU	1	0.40	2.5 (0.1, 9.2)	Fitted to CHESS
$I_{ICU_{W_R}}$	Hospitalised in ICU, leading to recovery	1	0.06	15.6 (0.4, 57.6)	Fitted to CHESS
I _{ICUWD}	Hospitalised in ICU, leading to death in step- down following ICU	1	0.14	7.0 (0.2, 25.7)	Fitted to CHESS
I _{ICUD}	Hospitalised in ICU, leading to death	2	0.17	11.8 (1.4, 32.9)	Fitted to CHESS
W _R	Stepdown recovery period after leaving ICU	2	0.16	12.2 (1.5, 34.0)	Fitted to CHESS
W _D	Stepdown period before death after leaving ICU	1	0.12	8.1 (0.2, 29.7)	Fitted to CHESS
R	Recovered	-	-	-	-
T_{pre}^{PCR}	Pre-PCR positive	1	0.33	3.0 (0.1, 11.1)	Omar et al. (16)
T_{pos}^{PCR}	True PCR positive	1	0.06	17.5 (0.4, 64.5)	-
T_{neg}^{PCR}	True PCR negative	-	-	-	
T_{pre}^{sero}	Pre-seroconversion	1	0.08	13.0 (0.3, 48.0)	Benny et al. (17)
T ^{sero} pos	True seropositive	-	-		-
T ^{sero} neg	True seronegative	-	-		-

214 Values of fitted parameters are set out in Table S 5.

215

216 1.3.3 Progression of infection and hospitalisation

217 The force of infection, $\lambda^i(t)$, for individuals in group $i \in \{[0,5), \dots, [75,80), [80 +), CHW, CHR\}$

218 depends on time-varying social mixing between age groups and prevalence in all age/care

219 home groups:

$$\lambda^{i}(t) = \sum_{j} m_{i,j}(t) \Pi_{j}(t)$$
⁽¹⁾

where $m_{i,j}(t)$ is the (symmetric) time-varying person-to-person transmission rate from group j to group i, and $\Pi_i(t)$ is the number of infectious individuals in group *j*, given by:

$$\Pi_j(t) = I_A^j(t) + I_c^j(t) \tag{2}$$

223

Broadly, to parameterise $m_{i,j}(t)$, we informed mixing in the general population, and between the general population and care home workers using POLYMOD (10) via the R package *socialmixr* using age-structured regional demography (18).

Transmission between different age groups $(i, j) \in \{[0,5), ..., [75,80), [80 +)\}^2$ was parameterised as follows:

$$m_{i,j}(t) = \beta(t)c_{i,j} \tag{3}$$

Here $c_{i,j}$ is the (symmetric) person-to-person contact rate between age group i and j, derived from pre-pandemic data (10). $\beta(t)$ is the time-varying transmission rate which encompasses both changes over time in transmission efficiency (e.g. due to temperature) and temporal changes in the overall level of contacts in the population (due to changes in policy and behaviours).

234 We assumed $\beta(t)$ to be piecewise linear:

$$\beta(t) = \begin{cases} \frac{\beta_1}{t_i - t} & \text{if } t \le t_1 \\ \frac{t_i - t_{i-1}}{t_i - t_{i-1}} \beta_{i-1} + \frac{t - t_{i-1}}{t_i - t_{i-1}} \beta_i, & \text{if } t_{i-1} < t \le t_i, \\ \beta_{13}, & \text{if } t > t_{13} \end{cases}$$
(4)

235

with 12 change points t_i corresponding to major announcements and changes in COVID-19 related policy, as detailed in Table S 3.

238

Description	Date	Value of $oldsymbol{eta}(t)$ at changepoint	Changepoint
PM makes speech advising working from home, against non-essential travel (19)	16/03/20	β_1	<i>t</i> ₁
PM announces lockdown 1 (20)	23/03/20	β_2	t_2
Lockdown 1 into full effect (21)	25/03/20	β_3	t_3
Initial easing of lockdown 1 (22)	11/05/20	β_4	t_4
Non-essential shops can re-open (23)	15/06/20	β_5	t_5
Restaurants, pubs etc can re-open (24)	04/07/20	β_6	t_6
"Eat out to help out" scheme starts (25)	03/08/20	β_7	<i>t</i> ₇
Schools and universities re-open (26)	01/09/20	β_8	t_8
"Rule of six" introduced (27)	14/09/20	β_9	<i>t</i> ₉
Tiered system introduced (28)	14/10/20	eta_{10}	t_{10}
Lockdown 2 announced (29)	31/10/20	β_{11}	t ₁₁
Lockdown 2 starts (29)	05/11/20	β_{12}	t_{12}

240 Table S 3: Changepoints for $\beta(t)$

 $\frac{1}{2}$ The contact matrix a between different are groupe (i, i) c

The contact matrix $c_{i,j}$ between different age groups $(i,j) \in \{[0,5), ..., [75,80), [80 +)\}^2$ is derived from the POLYMOD survey (10) for the United Kingdom using the *socialmixr* package (18,30), scaling by the local population demography to yield the required person-toperson daily contact rate matrix.

We defined parameters representing transmission rates within care homes (between and among workers and residents), which were assumed to be constant over time. Parameter m_{CHW} represents the person-to-person transmission rate among care home workers and between care home workers and residents; m_{CHR} represents the person-to-person

251 transmission rate among care home residents. Hence,

$$m_{CHW,CHW}(t) = m_{CHW,CHR}(t) = m_{CHW}$$
(5)

$$m_{CHR,CHR}(t) = m_{CHR} \tag{6}$$

- 252 Transmission between the general population and care home workers was assumed to be
- similar to that within the general population, accounting for the average age of care home
- 254 workers, with, for $i \in \{[0,5), \dots, [75,80), [80 +)\},\$

$$m_{i,CHW}(t) = \beta(t)c_{i,CHW} \tag{7}$$

- where $c_{i,CHW}$ is the mean of $c_{i,[25,30)}$, $c_{i,[30,35)}$, ..., $c_{i,[60,65)}$ (i.e. of the age groups that the care home workers are drawn from).
- 257 Transmission between the general population and care home residents was assumed to be
- similar to that between the general population and the 80+ age group, adjusted by a
- reduction factor (ϵ , which was estimated), such that, for $i \in \{[0,5), \dots, [75,80), [80 +)\}$,

$$m_{i,CHR}(t) = \epsilon \beta(t) c_{i,80+} \tag{8}$$

260 These represent contact between visitors from the general community and care home

residents. This might involve a slightly different age profile than the age profile of the contactmade by people in the 80+ age group.

263 1.3.4 Age-varying and time-varying infection progression probabilities

Various probabilities of clinical progression within the model are assumed to vary across age groups to account for severity of infection varying with age, and some are assumed to vary in time in order to model improvements in clinical outcomes, such as those achieved through the use of dexamethasone (31).

Two probabilities are age-varying but not time-varying, the probability of admission to hospital for symptomatic cases, and the probability of death for severe symptomatic cases in care homes. These were modelled as follows:

271

$$p_{H}^{i} = \psi_{H}^{i} p_{H}^{max}$$

$$p_{G_{D}}^{i} = \psi_{G_{D}}^{i} p_{G_{D}}^{max}$$

$$(9)$$

$$(10)$$

272

where for probability p_X^i , p_X^{max} is the maximum across all groups and ψ_X^i is the age scaling such that $\psi_X^i = 1$ for the group corresponding to the maximum, against which all other groups are scaled.

As well as varying with age, four probabilities also vary with time: the probability of
admission to ICU for hospitalised cases, the probability of death in ICU, the probability of
death for hospitalised cases not admitted to ICU, and the probability of death in hospital after
discharge from ICU:

280

$$p_{ICU}^{i}(t) = \psi_{ICU}^{i} p_{ICU}^{max} h(\mu_{ICU}, t)$$
(11)

$$p_{ICU_{D}}^{i}(t) = \psi_{ICU_{D}}^{i} p_{ICU_{D}}^{max} h(\mu_{D}, t)$$
(12)

$$p_{H_D}^i(t) = \psi_{H_D}^i p_{H_D}^{max} h(\mu_D, t)$$
(13)

$$p_{W_D}^i(t) = \psi_{W_D}^i p_{W_D}^{max} h(\mu_D, t)$$
(14)

281

where here for probability p_X^i , p_X^{max} gives the maximum *initial* value across groups and

283 $h(\mu, t) = 1$ before April 1st, $h(\mu, t) = \mu < 1$ after June 1st, with a linear reduction in between.

284

Care home residents with severe disease leading to death are assumed to remain in compartment G_D for 5 days on average before dying (modelled with $k_{G_D} = 2$ and $\gamma_{G_D} = 0.4$), 95% range 0.6-13.9 days broadly consistent with durations in (15) and with duration about

half the length observed in hospital streams (see Figure S 5).

289

For care home workers, the age scaling ψ_X^{CHW} is taken as the mean of the age scalings ψ_X^i for $i \in \{[25,30), [30,35), \dots, [60,65)\}$. For care home residents, we assume that $\psi_X^{CHR} = \psi_X^{(80+)}$

292 $\psi_X^{[80+)}$, with the exception of the probability of individual with severe disease requiring

hospitalisation dying at home (without receiving hospital care), where we assume $\psi_{G_D}^{CHR} = 1$

and $\psi_{G_D}^i = 0$ for all other groups, to effectively allow death outside hospital only for care home residents.

296 **1.4** Reproduction number R_t and effective reproduction number R_t^{eff}

We calculated the reproduction number over time, R_t , and effective reproduction number over time, R_t^{eff} , using next generation matrix methods (32). The reproduction numbers are calculated for the general population, i.e. excluding care home workers and residents. We define R_t as the average number of secondary infections a case infected at time t would generate in a large entirely susceptible population, and R_t^{eff} as the average number of

302 secondary infections generated by a case infected at time t would accounting for the finite 303 population size and potential immunity in the population.

To compute the next generation matrix, we calculated the mean duration of infectiousness Δ_I , as

$$\Delta_I = (1 - p_C) \mathbb{E}[\tau_{I_A}] + p_C \mathbb{E}[\tau_{I_C}]$$
⁽¹⁵⁾

306

where parameter and model compartment notations are defined in Table S 2 - Table S 8. For this calculation, the expected durations of stay in compartments were adjusted to account for the discrete-time nature of the model, via calculating the expected number of time-steps (of length dt) spent in a given compartment. Note that if in continuous-time a compartment duration is $\tau \sim \text{Erlang}(k, \gamma)$, then the corresponding discrete-time mean

312 duration is:

$$E[\tau] = \frac{k \, dt}{(1 - e^{-\gamma dt})} \tag{16}$$

313 The next generation matrix was calculated as, for
$$(i, j) \in \{[0,5), ..., [75,80), [80 +)\}^2$$
,
314

$$\mathrm{NGM}_{ij}(t) = m_{ij}(t)\Delta_I N^i \tag{17}$$

315

where N^i is the total population of group *i* and R_t is taken to be the dominant eigenvalue of NGM(*t*), while the effective next generation matrix was calculated as:

318

$$NGM_{ii}^{eff}(t) = m_{ij}(t)\Delta_I S^i(t)$$
(18)

319 with R_t^{eff} taken to be the dominant eigenvalue of NGM^{eff}(t).

320

321 1.5 Infection severity

Posterior estimates of severity, namely the infection hospitalisation and infection fatality ratios, were calculated in each group *i* as follows:

$$IHR^{i} = p_{C} p_{H}^{i} (1 - p_{G_{D}}^{i})$$
(19)

$$IFR^{i}(t) = p_{C}p_{H}^{i} \left\{ p_{G_{D}}^{i} + (1 - p_{G_{D}}^{i}) \left(p_{ICU}^{i}(t) \left(p_{ICU_{D}}^{i}(t) + (1 - p_{ICU_{D}}^{i}(t)) p_{W_{D}}^{i}(t) \right) + (1 - p_{ICU}^{i}(t)) p_{H_{D}}^{i}(t) \right) \right\}$$

$$(20)$$

Note that for simplicity the notation we use do refer explicitly to the NHS region of interest.
We calculated age-aggregated estimates for each region by weighting the age-specific
severity estimates by the cumulative incidence in that age group. Aggregate estimates for
England were then calculated by weighting the region-specific estimates by the regional
attack rates.

331

332 **1.6 Compartmental model equations**

To clearly illustrate the model dynamics, we describe a deterministic version of the model in differential equations (22)-(57), followed by the stochastic implementation used in the

analysis. Each compartment is stratified by mixing category $i \in$

 $\{[0,5), ..., [75,80), [80+), CHW, CHR\}$. Full definitions of compartments and model parameters are set out in Table S 2 - Table S 8.

$$dS^{i}(t)/dt = -\lambda^{i}(t)S^{i}(t)$$
⁽²¹⁾

$$dE^{i,1}(t)/dt = \lambda^{i}(t)S^{i}(t) - \gamma_{E}E^{i,1}(t)$$
(22)

$$dE^{i,2}(t)/dt = \gamma_E E^{i,1}(t) - \gamma_E E^{i,2}(t)$$
(23)

$$dI_{A}^{i}(t)/dt = (1 - p_{C})\gamma_{E}E^{i,2}(t) - \gamma_{A}I_{A}^{i}(t)$$
(24)

$$dI_{c}^{i}(t)/dt = p_{c}\gamma_{E}E^{i,2}(t) - \gamma_{c}I_{c}^{i}(t)$$
(25)

$$dG_{D}^{i,1}(t)/dt = p_{H}^{i} p_{G_{D}}^{i} \gamma_{C} I_{C}^{i}(t) - \gamma_{G_{D}} G_{D}^{i,1}(t)$$
(26)

$$dG_D^{i,2}(t)/dt = \gamma_{G_D} G_D^{i,1}(t) - \gamma_{G_D} G_D^{i,2}(t)$$
(27)

$$dICU_{pre}^{i}(t)/dt = p_{H}^{i}(1-p_{G_{D}}^{i})(1-p^{*}(t)) p_{ICU}^{i}(t) \gamma_{C}I_{C}^{i}(t) - (\gamma_{ICU_{pre}} + \gamma_{U}) ICU_{pre}^{i}(t)$$
(28)

$$dICU^{i}_{pre^{*}}(t)/dt = p^{i}_{H}(1 - p^{i}_{G_{D}})p^{*}(t) p^{i}_{ICU}(t)\gamma_{C}I^{i}_{C}(t) - \gamma_{ICU_{pre}}ICU^{i}_{pre^{*}}(t) + \gamma_{U}ICU^{i}_{pre}(t)$$
(29)

$$dICU_{W_R}^{i}(t)/dt = \left(1 - p_{ICU_D}^{i}(t)\right)\left(1 - p_{W_D}^{i}(t)\right)\gamma_{ICU_{pre}}ICU_{pre}^{i}(t) - \left(\gamma_{ICU_{W_R}} + \gamma_U\right)ICU_{W_R}^{i}(t)$$
(30)

$$dICU_{W_{R^{*}}}^{i}(t)/dt = (1 - p_{ICU_{D}}^{i}(t))(1 - p_{W_{D}}^{i}(t))\gamma_{ICU_{pre}}ICU_{pre^{*}}^{i}(t) - \gamma_{ICU_{W_{R}}}ICU_{W_{R^{*}}}^{i}(t) + \gamma_{U}ICU_{W_{R}}^{i}(t)$$
(31)

$$dICU_{W_{D}}^{i}(t)/dt = \left(1 - p_{ICU_{D}}^{i}(t)\right)p_{W_{D}}^{i}(t)\gamma_{ICU_{pre}}ICU_{pre}^{i}(t) - \left(\gamma_{ICU_{W_{D}}} + \gamma_{U}\right)ICU_{W_{D}}^{i}(t)$$
(32)

$$dICU_{W_{D^*}}^{i}(t)/dt = (1 - p_{ICU_{D}}^{i}(t))p_{W_{D}}^{i}(t)\gamma_{ICU_{pre}}ICU_{pre^{*}}^{i}(t) - \gamma_{ICU_{W_{D}}}ICU_{W_{D^{*}}}^{i}(t) + \gamma_{U}ICU_{W_{D}}^{i}(t)$$
(33)

$$dICU_D^{i,1}(t)/dt = p_{ICU_D}^i(t)\gamma_{ICU_{pre}}ICU_{pre}^i(t) - \left(\gamma_{ICU_D} + \gamma_U\right)ICU_D^{i,1}(t)$$
(34)

$$dICU_{D}^{i,2}(t)/dt = \gamma_{ICU_{D}}ICU_{D}^{i,1}(t) - (\gamma_{ICU_{D}} + \gamma_{U})ICU_{D}^{i,2}(t)$$
(35)

$$dICU_{D^{*}}^{i,1}(t)/dt = p_{ICU_{D}}^{i}(t)\gamma_{ICU_{pre}}ICU_{pre^{*}}^{i}(t) - \gamma_{ICU_{D}}ICU_{D^{*}}^{i,1}(t) + \gamma_{U}ICU_{D}^{i,1}(t)$$
(36)

$$dICU_{D^{*}}^{i,2}(t)/dt = \gamma_{ICU_{D}}ICU_{D^{*}}^{i,1}(t) - \gamma_{ICU_{D}}ICU_{D^{*}}^{i,2}(t) + \gamma_{U}ICU_{D}^{i,2}(t)$$
(37)

$$dW_{R}^{i,1}(t)/dt = \gamma_{ICU_{W_{R}}} ICU_{W_{R}}^{i}(t) - (\gamma_{W_{R}} + \gamma_{U}) W_{R}^{i,1}(t)$$
(38)

$$dW_{R}^{i,2}(t)/dt = \gamma_{W_{R}}W_{R}^{i,1}(t) - (\gamma_{W_{R}} + \gamma_{U})W_{R}^{i,2}(t)$$
(39)

$$dW_{R^*}^{i,1}(t)/dt = \gamma_{ICU_{W_R}} ICU_{W_{R^*}}^i(t) - \gamma_{W_R} W_{R^*}^{i,1}(t) + \gamma_U W_{R}^{i,1}(t)$$
(40)

$$dW_{R^*}^{i,2}(t)/dt = \gamma_{W_R} W_{R^*}^{i,1}(t) - \gamma_{W_R} W_{R^*}^{i,2}(t) + \gamma_U W_{R^*}^{i,2}(t)$$
(41)

$$dW_D^i(t)/dt = \gamma_{ICU_{W_D}} ICU_{W_D}^i(t) - (\gamma_{W_D} + \gamma_U) W_D^i(t)$$

$$\tag{42}$$

$$dW_{D^*}^i(t)/dt = \gamma_{ICU_{W_D}} ICU_{W_{D^*}}^i(t) - \gamma_{W_D} W_{D^*}^i(t) + \gamma_U W_D^i(t)$$
(43)

$$dH_{R}^{i}(t)/dt = p_{H}^{i} (1 - p_{G_{D}}^{i}) (1 - p^{*}(t)) (1 - p_{ICU}^{i}(t)) (1 - p_{H_{D}}^{i}(t)) \gamma_{C} I_{C}^{i}(t) - (\gamma_{H_{R}} + \gamma_{U}) H_{R}^{i}(t)$$
(44)

$$dH_{R^*}^i(t)/dt = p_H^i (1 - p_{G_D}^i) p^*(t) (1 - p_{ICU}^i(t)) (1 - p_{H_D}^i(t)) \gamma_C I_C^i(t) + \gamma_U H_R^i(t) - \gamma_{H_R} H_{R^*}^i(t)$$
(45)

$$dH_D^{i,1}(t)/dt = p_H^i (1 - p_{G_D}^i) (1 - p^*(t)) (1 - p_{ICU}^i(t)) p_{H_D}^i(t) \gamma_C I_C^i(t) - (\gamma_{H_D} + \gamma_U) H_D^{i,1}(t)$$
(46)

$$dH_D^{i,2}(t)/dt = \gamma_{H_D} H_D^{i,1}(t) - (\gamma_{H_D} + \gamma_U) H_D^{i,2}(t)$$
(47)

$$dH_{D^*}^{i,1}(t)/dt = p_H^i (1 - p_{G_D}^i) p^*(t) (1 - p_{ICU}^i(t)) p_{H_D}^i(t) \gamma_C I_C^i(t) + \gamma_U H_D^{i,1}(t) - \gamma_{H_D} H_{D^*}^{i,1}(t)$$
(48)

$$dH_{D^*}^{i,2}(t)/dt = \gamma_{H_D} H_{D^*}^{i,1}(t) - \gamma_{H_D} H_{D^*}^{i,2}(t) + \gamma_U H_D^{i,2}(t)$$
(49)

$$dR^{i}(t)/dt = \gamma_{A}I_{A}^{i}(t) + \left(1 - p_{H}^{i}\right)\gamma_{C}I_{C}^{i}(t) + \gamma_{H_{R}}\left(H_{R}^{i}(t) + H_{R^{*}}^{i}(t)\right) + \gamma_{W_{R}}\left(W_{R}^{i}(t) + W_{R^{*}}^{i}(t)\right)$$
(50)

$$dT_{seropre}^{i}(t)/dt = \gamma_{E}E^{i,2}(t) - \gamma_{seropre}T_{seropre}^{i}(t)$$
(51)

$$dT_{sero_{pos}}^{i}(t)/dt = p_{sero_{pos}}\gamma_{sero_{pre}}T_{PCR_{pre}}^{i}(t)$$
(52)

$$dT^{i}_{sero_{neg}}(t)/dt = \left(1 - p_{sero_{pos}}\right)\gamma_{sero_{pre}}T^{i}_{PCR_{pre}}(t)$$
(53)

$$dT^{i}_{PCR_{pre}}(t)/dt = \lambda^{i}(t)S^{i}(t) - \gamma_{PCR_{pre}}T^{i}_{PCR_{pre}}(t)$$
(54)

$$dT^{i}_{PCR_{pos}}(t)/dt = \gamma_{PCR_{pre}}T^{i}_{PCR_{pre}}(t) - \gamma_{PCR_{pos}}T^{i}_{PCR_{pos}}(t)$$
(55)

$$dT^{i}_{PCR_{neg}}(t)/dt = \gamma_{PCR_{pos}}T^{i}_{PCR_{pos}}(t)$$
(56)

We used the tau-leap method (33) to create a stochastic, time-discretised version of the model described in equations (58-162), taking four update steps per day. The process was initialised with ten asymptomatic infectious individuals aged 15-19 on the epidemic start date t_0 , a parameter we estimate. For each time step, the model iterated through the procedure described below. In the following, we introduce a small abuse of notation: for transitions involving multiple onward compartments (e.g transition from compartment *E* to

346 compartments I_A or I_C), for conciseness, we write

$$\begin{pmatrix} d_{E,I_A}^i, d_{E,I_C}^i \end{pmatrix}$$
 ~ Multinom $\begin{pmatrix} E^{i,2}(t), q_{E,I_A}^i, q_{E,I_C}^i \end{pmatrix}$

347 instead of

$$\left(d_{E,I_A}^i, \ d_{E,I_C}^i, d_{nomove}^i \right) \quad \sim \text{Multinom} \left(E^{i,2}(t), \ q_{E,I_A}^i, \ q_{E,I_C}^i, \ 1 - \sum_{x \in \{I_A,I_C\}} q_{E,x}^i \right)$$

348 where d_{nomove}^{i} is a dummy variable counting the number of individuals remaining in compartment 349 $E^{i,2}$.

Using this convention, transition variables are drawn from the following distributions, withprobabilities defined below:

$$d_{S,E}^{i} \sim \text{Binom}\left(S^{i}(t), \ 1 - e^{-\lambda^{i}(t)dt}\right)$$
(57)

$$d_{E,E}^{i} \sim \text{Binom} \left(E^{i,1}(t), \ 1 - e^{-\gamma_{E} dt} \right)$$
 (58)

$$(q_{E,I_A}^i, q_{E,I_C}^i) = ((1 - p_C)(1 - e^{-\gamma_E dt}), p_C(1 - e^{-\gamma_E dt}))$$
(59)

$$\left(d_{E,I_A}^i, d_{E,I_C}^i\right) \sim \operatorname{Multinom}\left(E^{i,2}(t), q_{E,I_A}^i, q_{E,I_C}^i\right)$$
(60)

$$d_{I_{A},R}^{i} \sim \operatorname{Binom}\left(I_{A}^{i}(t), 1 - e^{-\gamma_{A}dt}\right)$$
(61)

$$q_{I_{C},G_{D}}^{i} = p_{H}^{i} p_{G_{D}}^{i} (1 - e^{-\gamma_{C} dt})$$
(62)

$$q_{I_{C,R}}^{i} = (1 - p_{H}^{i})(1 - e^{-\gamma_{C}dt})$$
(63)

$$q_{I_{C,ICU_{pre}}}^{i} = p_{H}^{i} \left(1 - p_{G_{D}}^{i}\right) \left(1 - p^{*}(t)\right) p_{I_{CU}}^{i}(t) \left(1 - e^{-\gamma_{C} dt}\right)$$
(64)

$$q_{I_{C},ICU_{pre^{*}}}^{i} = p_{H}^{i} \left(1 - p_{G_{D}}^{i}\right) p^{*}(t) p_{ICU}^{i}(t) \left(1 - e^{-\gamma_{C} dt}\right)$$
(65)

$$q_{I_{C},H_{R}}^{i} = p_{H}^{i} \left(1 - p_{G_{D}}^{i}\right) \left(1 - p^{*}(t)\right) \left(1 - p_{I_{CU}}^{i}(t)\right) \left(1 - p_{H_{D}}^{i}(t)\right) \left(1 - e^{-\gamma_{C}dt}\right)$$
(66)

$$q_{I_{C},H_{R}^{*}}^{i} = p_{H}^{i} \left(1 - p_{G_{D}}^{i}\right) p^{*}(t) \left(1 - p_{I_{C}U}^{i}(t)\right) \left(1 - p_{H_{D}}^{i}(t)\right) \left(1 - e^{-\gamma_{C}dt}\right)$$
(67)

$$q_{I_{C},H_{D}}^{i} = p_{H}^{i} \left(1 - p_{G_{D}}^{i}\right) \left(1 - p^{*}(t)\right) \left(1 - p_{ICU}^{i}(t)\right) p_{H_{D}}^{i}(t) \left(1 - e^{-\gamma_{C} dt}\right)$$
(68)

$$q_{I_{C},H_{D^{*}}}^{i} = p_{H}^{i} \left(1 - p_{G_{D}}^{i}\right) p^{*}(t) \left(1 - p_{ICU}^{i}(t)\right) p_{H_{D}}^{i}(t) (1 - e^{-\gamma_{C} dt})$$
(69)

$$\begin{pmatrix} d_{I_{C},G_{D}}^{i}, \dots, d_{I_{C},H_{D^{*}}}^{i} \end{pmatrix} \sim \operatorname{Multinom} \left(I_{C}^{i}(t), q_{I_{C},G_{D}}^{i}, \dots, q_{I_{C},H_{D^{*}}}^{i} \right)$$

$$d_{G_{D},G_{D}}^{i} \sim \operatorname{Binom} \left(G_{D}^{i,1}(t), \ 1 - e^{-\gamma_{G_{D}}dt} \right)$$

$$(70)$$

$$\sum_{D,G_D} \sim \operatorname{Binom}\left(G_D(t), 1 - e^{-\gamma c_D}dt\right) \tag{71}$$

$$d_{G_D,D}^i \sim \operatorname{Binom}\left(G_D^{i,2}(t), \ 1 - e^{-\gamma_{G_D}dt}\right)$$
(72)

$$q_{ICU_{pre,ICU_{W_{R}}}}^{i} = \left(1 - p_{ICU_{D}}^{i}(t)\right) \left(1 - p_{W_{D}}^{i}(t)\right) \left(1 - e^{-\gamma_{ICU_{pre}}dt}\right) e^{-\gamma_{U}dt}$$
(73)
$$q_{ICU_{pre,ICU_{W_{R^{*}}}}}^{i} = \left(1 - p_{ICU_{D}}^{i}(t)\right) \left(1 - p_{W_{D}}^{i}(t)\right) \left(1 - e^{-\gamma_{ICU_{pre}}dt}\right) (1 - e^{-\gamma_{U}dt})$$
(74)

$$q_{ICU_{pre},ICU_{W_{R^{*}}}}^{i} = \left(1 - p_{ICU_{D}}^{i}(t)\right) \left(1 - p_{W_{D}}^{i}(t)\right) \left(1 - e^{-\gamma_{ICU_{pre}}at}\right) (1 - e^{-\gamma_{U}dt})$$
(74)
$$q_{ICU_{pre},ICU_{W_{D}}}^{i} = \left(1 - p_{ICU_{D}}^{i}(t)\right) p_{W_{D}}^{i}(t) \left(1 - e^{-\gamma_{ICU_{pre}}dt}\right) e^{-\gamma_{U}dt}$$
(75)

$$u_{pre,ICU_{W_D}} = \left(1 - p_{ICU_D}^i(t)\right) p_{W_D}^i(t) \left(1 - e^{-\gamma_{ICU_{pre}}dt}\right) e^{-\gamma_U dt}$$
(75)

$$q_{ICU_{pre},ICU_{W_{D^{*}}}}^{i} = \left(1 - p_{ICU_{D}}^{i}(t)\right) p_{W_{D}}^{i}(t) \left(1 - e^{-\gamma_{ICU_{pre}}dt}\right) (1 - e^{-\gamma_{U}dt})$$
(76)
$$q_{ICU_{pre},ICU_{D}}^{i} = p_{ICU_{D}}^{i}(t) \left(1 - e^{-\gamma_{ICU_{pre}}dt}\right) e^{-\gamma_{U}dt}$$
(77)

$$e^{ICU_D} = p^i_{ICU_D}(t) \left(1 - e^{-\gamma_{ICU_{pre}}dt}\right) e^{-\gamma_{U}dt}$$

$$\tag{77}$$

$$q_{ICU_{pre},ICU_{D^{*}}}^{i} = p_{ICU_{D}}^{i}(t) (1 - e^{-\gamma_{ICU_{pre}}dt}) (1 - e^{-\gamma_{U}dt})$$

$$q_{ICU_{pre},ICU_{pre^{*}}}^{i} = e^{-\gamma_{ICU_{pre}}dt} (1 - e^{-\gamma_{U}dt})$$
(78)
(79)

$$e_{re,ICU_{pre^*}} = e^{-\gamma_{ICU_{pre}}dt} (1 - e^{-\gamma_U dt})$$
(79)

$$\begin{pmatrix} d_{ICU_{pre},ICU_{W_R}}^i, \dots, d_{ICU_{pre},ICU_{pre}}^i \end{pmatrix} \sim \text{Multinom} \left(ICU_{pre}^i(t), q_{ICU_{pre},ICU_{W_R}}^i, \dots, q_{ICU_{pre},ICU_{pre}}^i \right)$$

$$q_{ICU_{pre},ICU_{W_R^*}}^i = \left(1 - p_{ICU_D}^i(t) \right) \left(1 - p_{W_D}^i(t) \right) \left(1 - e^{-\gamma_{ICU_{pre}}dt} \right)$$

$$(80)$$

$$CU_{pre,ICU_{W_{R^*}}}^* = \left(1 - p_{ICU_D}^i(t)\right) \left(1 - p_{W_D}^i(t)\right) \left(1 - e^{-\gamma_{ICU_{pre}}at}\right)$$
(81)

$$q_{ICU_{pre},ICU_{W_{D^{*}}}}^{i} = \left(1 - p_{ICU_{D}}^{i}(t)\right) p_{W_{D}}^{i}(t) \left(1 - e^{-\gamma_{ICU_{pre}}dt}\right)$$
(82)

$$q_{ICU_{pre},ICU_{D^{*}}}^{i} = p_{ICU_{D}}^{i}(t) \left(1 - e^{-\gamma_{ICU_{pre}}dt}\right)$$
(83)

$$\left(d^{i}_{ICU^{*}_{pre,ICU}_{W_{R^{*}}}}, \dots, d^{i}_{ICU^{*}_{pre,ICU_{D^{*}}}}\right) \sim \text{Multinom}\left(ICU^{i}_{pre^{*}}(t), q^{i}_{ICU^{*}_{pre,ICU}_{W_{R^{*}}}}, \dots, q^{i}_{ICU^{*}_{pre,ICU_{D^{*}}}}\right)$$

$$(84)$$

$$q_{H_D,H_D}^i = \left(1 - e^{-\gamma_{H_D}dt}\right)e^{-\gamma_U dt} \tag{85}$$

$$q_{H_D,H_{D^*}}^{i,1,1} = e^{-\gamma_{H_D}dt}(1 - e^{-\gamma_U dt})$$
(86)

$$q_{H_D,H_{D^*}}^{i,1,2} = \left(1 - e^{-\gamma_{H_D}dt}\right) (1 - e^{-\gamma_U dt})$$
(87)

$$\begin{pmatrix} d_{H_{D},H_{D}}^{i}, d_{H_{D},H_{D^{*}}}^{i,1,1}, d_{H_{D},H_{D^{*}}}^{i,1,2} \end{pmatrix} \sim \text{Multinom} \begin{pmatrix} H_{D}^{i,1}(t), q_{H_{D},H_{D}}^{i}, q_{H_{D},H_{D^{*}}}^{i,1,1}, q_{H_{D},H_{D^{*}}}^{i,1,2} \end{pmatrix}$$

$$\begin{pmatrix} d_{H_{D},H_{D^{*}}}^{i}, d_{H_{D},H_{D^{*}}}^{i,1,2} \end{pmatrix} \qquad (88)$$

$$d_{H_{D^{*},H_{D^{*}}}}^{i} \sim \text{Binom} \left(H_{D^{*}}^{i,1}(t), 1 - e^{-\gamma_{H_{D}}dt} \right)$$

$$\qquad (89)$$

$$_{D^{*},H_{D^{*}}} \sim \operatorname{Binom}\left(H_{D^{*}}^{i,1}(t), 1 - e^{-\gamma_{H_{D}}dt}\right)$$
(89)

$$\begin{pmatrix} d_{H_{D},D}^{i}, d_{H_{D},H_{D^{*}}}^{i,2,2} \end{pmatrix} \sim \text{Multinom} \begin{pmatrix} H_{D}^{i,2}(t), \ 1 - e^{-\gamma_{H_{D}}dt}, e^{-\gamma_{H_{D}}dt}(1 - e^{-\gamma_{U}dt}) \end{pmatrix}$$

$$d_{H_{D^{*},D}}^{i} \sim \text{Binom} \begin{pmatrix} H_{D^{*}}^{i,2}(t), \ 1 - e^{-\gamma_{H_{D}}dt} \end{pmatrix}$$

$$(90)$$

$$H_{D^*,D} \sim \text{Binom}\left(H_{D^*}^{i,2}(t), \ 1 - e^{-\gamma_{H_D}dt}\right)$$
 (91)

$$\begin{pmatrix} d_{H_R,R}^i, d_{H_R,H_R^*}^i \end{pmatrix} \sim \text{Multinom} \begin{pmatrix} H_R^i(t), \ 1 - e^{-\gamma_{H_R}dt}, e^{-\gamma_{H_R}dt} (1 - e^{-\gamma_U dt}) \end{pmatrix}$$

$$d_{H_R^*,R}^i \sim \text{Binom} \begin{pmatrix} H_R^i(t), \ 1 - e^{-\gamma_{H_R}dt} \end{pmatrix}$$

$$(92)$$

$$_{*,R} \sim \operatorname{Binom}\left(H_{R^*}^i(t), \ 1 - e^{-\gamma_{H_R}dt}\right)$$
(93)

$$q_{ICU_{W_R},W_R}^i = \left(1 - e^{-\gamma_{ICU_{W_R}}dt}\right) e^{-\gamma_U dt}$$
(94)

$$q_{ICU_{W_R},ICU_{W_R^*}}^i = e^{-\gamma_{ICU_{W_R}}dt} (1 - e^{-\gamma_U dt})$$
(95)

$$q_{ICU_{W_R},W_{R^*}}^i = \left(1 - e^{-\gamma_{ICU_{W_R}}dt}\right) (1 - e^{-\gamma_{U}dt})$$
(96)

$$\left(d_{ICU_{W_{R}},W_{R}}^{i},\ldots,d_{ICU_{W_{R}},W_{R^{*}}}^{i}\right) \sim \text{Multinom}\left(ICU_{W_{R}}^{i}(t),q_{ICU_{W_{R}},W_{R}}^{i},\ldots,q_{ICU_{W_{R}},W_{R^{*}}}^{i}\right)$$
(97)

$$d^{i}_{ICU_{W_{R^{*}},W_{R^{*}}}} \sim \text{Binom}\left(ICU^{i}_{W_{R^{*}}}(t), \ 1 - e^{-\gamma_{ICU_{W_{R}}}dt}\right)$$
(98)
$$q^{i}_{ICU_{W_{D}},W_{D}} = \left(1 - e^{-\gamma_{ICU_{W_{D}}}dt}\right)e^{-\gamma_{U}dt}$$
(99)

$$J_{W_D}, W_D = \left(1 - e^{-\gamma_{ICU}}W_D^{dt}\right) e^{-\gamma_U dt}$$
(99)

$$q_{ICU_{W_D},ICU_{W_D^*}}^i = e^{-\gamma_{ICU_{W_D}}dt} (1 - e^{-\gamma_U dt})$$
(100)

$$q_{ICU_{W_D},W_D^*}^i = \left(1 - e^{-\gamma_{ICU_{W_D}}dt}\right) (1 - e^{-\gamma_{U}dt})$$
(101)

$$\begin{pmatrix} d^{i}_{ICU_{W_{D}},W_{D}}, \dots, d^{i}_{ICU_{W_{D}},W_{D^{*}}} \end{pmatrix} \sim \text{Multinom} \left(ICU^{i}_{W_{D}}(t), q^{i}_{ICU_{W_{D}},W_{D}}, \dots, q^{i}_{ICU_{W_{D}},W_{D^{*}}} \right)$$

$$d^{i}_{ICU_{W_{D^{*}}},W_{D^{*}}} \sim \text{Binom} \left(ICU^{i}_{W_{D^{*}}}(t), \ 1 - e^{-\gamma_{ICU_{W_{D}}}dt} \right)$$

$$(102)$$

$$c_{UW_{D^*},W_{D^*}} \sim \text{Binom}\left(ICU^i_{W_{D^*}}(t), \ 1 - e^{-\gamma_{IC}y_{W_D}at}\right)$$
 (103)

$$q_{ICU_D,ICU_D}^i = \left(1 - e^{-\gamma_I CU_D dt}\right) e^{-\gamma_U dt}$$
(104)

$$q_{ICU_{D},ICU_{D^{*}}}^{i,1,1} = e^{-\gamma_{ICU_{D}}dt}(1 - e^{-\gamma_{U}dt})$$
(105)

$$q_{ICU_{D},ICU_{D^{*}}}^{i,1,2} = \left(1 - e^{-\gamma_{ICU_{D}}dt}\right)\left(1 - e^{-\gamma_{U}dt}\right)$$
(106)

$$\left(d_{ICU_{D},ICU_{D}}^{i}, d_{ICU_{D},ICU_{D^{*}}}^{i,1,1}, d_{ICU_{D},ICU_{D^{*}}}^{i,1,2}\right) \sim \text{Multinom}\left(ICU_{D}^{i,1}(t), q_{ICU_{D},ICU_{D}}^{i}, q_{ICU_{D},ICU_{D^{*}}}^{i,1,1}, q_{ICU_{D},ICU_{D^{*}}}^{i,1,2}, q_{ICU_{D},ICU_{D^{*}}}^{i,1,2}\right)$$
(107)

$$d_{ICU_{D^*}, ICU_{D^*}}^i \sim \text{Binom}\left(ICU_{D^*}^{i,1}(t), \ 1 - e^{-\gamma_{ICU_D}dt}\right)$$
(108)

$$\left(d_{ICU_{D},D}^{i}, d_{ICU_{D},ICU_{D}^{*}}^{i,2,2}\right) \sim \text{Multinom}\left(ICU_{D}^{i,2}(t), \ 1 - e^{-\gamma_{ICU_{D}}dt}, e^{-\gamma_{ICU_{D}}dt}(1 - e^{-\gamma_{U}dt})\right)$$
(109)

$$d_{ICU_{D^*},D}^i \sim \operatorname{Binom}\left(ICU_{D^*}^{i,2}(t), \ 1 - e^{-\gamma_{IC}U_D dt}\right)$$
(110)

$$q_{W_R,W_R}^i = \left(1 - e^{-\gamma_W_R dt}\right) e^{-\gamma_U dt} \tag{111}$$

$$q_{W_R,W_{R^*}}^{i,1,1} = e^{-\gamma_W_R dt} (1 - e^{-\gamma_U dt})$$
(112)

$$q_{W_R,W_R^*}^{i,1,2} = \left(1 - e^{-\gamma_W_R dt}\right) (1 - e^{-\gamma_U dt})$$
(113)

$$\left(d_{W_{R},W_{R}}^{i}, d_{W_{R},W_{R}^{*}}^{i,1,1}, d_{W_{R},W_{R}^{*}}^{i,1,2}\right) \sim \text{Multinom}\left(W_{R}^{i,1}(t), q_{W_{R},W_{R}}^{i}, q_{W_{R},W_{R}^{*}}^{i,1,1}, q_{W_{R},W_{R}^{*}}^{i,1,2}\right)$$
(114)

$$d^{i}_{W_{R^{*},W_{R^{*}}}} \sim \text{Binom}\left(W^{i,1}_{R^{*}}(t), \ 1 - e^{-\gamma_{W_{R}}dt}\right)$$
(115)

$$\left(d_{W_{R},R}^{i}, d_{W_{R},W_{R^{*}}}^{i,2,2}\right) \sim \text{Multinom}\left(W_{R}^{i,2}(t), \ 1 - e^{-\gamma_{W_{R}}dt}, e^{-\gamma_{W_{R}}dt}(1 - e^{-\gamma_{U}dt})\right)$$
(116)

$$d^{i}_{W_{R^{*},R}} \sim \operatorname{Binom}\left(W^{i,2}_{R^{*}}(t), \ 1 - e^{-\gamma_{W_{R}}dt}\right)$$
 (117)

$$\begin{pmatrix} d_{W_D,D}^i, d_{W_D,W_D^*}^i \end{pmatrix} \sim \text{Multinom} \begin{pmatrix} W_D^i(t), \ 1 - e^{-\gamma_{W_D}dt}, e^{-\gamma_{W_D}dt}(1 - e^{-\gamma_U dt}) \end{pmatrix}$$

$$d_{W_D^*,D}^i \sim \text{Binom} \begin{pmatrix} W_D^i(t), \ 1 - e^{-\gamma_{W_D}dt} \end{pmatrix}$$

$$(118)$$

$$(119)$$

$$\mathcal{W}_{D^{*},D} \sim \operatorname{Binom}\left(\mathcal{W}_{D^{*}}^{i}(t), \ 1 - e^{-\gamma_{W_{D}}dt}\right)$$
(119)

$$\left(d_{W_D,D}^i, d_{W_D,W_D^*}^i\right) \sim \text{Multinom}\left(W_D^i(t), \quad 1 - e^{-\gamma_{W_D}dt}, e^{-\gamma_{W_D}dt}(1 - e^{-\gamma_U dt})\right)$$
(120)

$$q_{T_{seropre},T_{seropos}}^{i} = p_{seropos} \left(1 - e^{-\gamma_{seropre}dt}\right)$$
(121)

$$q_{T_{seropre},T_{seroneg}}^{i} = \left(1 - p_{sero_{pos}}\right) \left(1 - e^{-\gamma_{seropre}dt}\right)$$
(122)

$$\begin{pmatrix} d^{i}_{T_{seropre}, T_{seropos}}, d^{i}_{T_{seropre}, T_{seroneg}} \end{pmatrix} \sim \text{Multinom} \begin{pmatrix} T^{i}_{seropre}(t), q^{i}_{T_{seropre}, T_{seropos}}, q^{i}_{T_{seropre}, T_{seroneg}} \end{pmatrix}$$
(123)
$$d^{i}_{T_{PCR_{nrea}}, T_{PCR_{nree}}} \sim \text{Binom} \begin{pmatrix} T^{i}_{PCR_{nree}}(t), 1 - e^{-\gamma_{PCR_{pre}}dt} \end{pmatrix}$$
(124)

$$_{PCR_{pre}, T_{PCR_{pos}}} \sim \operatorname{Binom}\left(T^{i}_{PCR_{pre}}(t), \ 1 - e^{-\gamma_{PCR_{pre}}dt}\right)$$
 (124)

......

$$d_{T_{PCR_{pos}},T_{PCR_{neg}}}^{i} \sim \text{Binom}\left(T_{PCR_{pos}}^{i}(t), \ 1 - e^{-\gamma_{PCR_{pos}}dt}\right)$$
(125)

Model compartments were then updated as follows:

$$S^{i}(t+dt) := S^{i}(t) - d^{i}_{S,E}$$
(126)

$$E^{i,1}(t+dt) := E^{i,1}(t) + d^i_{S,E} - d^i_{E,E}$$
(127)

$$E^{i,2}(t+dt) \coloneqq E^{i,2}(t) + d^i_{E,E} - d^i_{E,I_A} - d^i_{E,I_C}$$
(128)

$$I_{A}^{i}(t+dt) := I_{A}^{i}(t) + d_{E,I_{A}}^{i} - d_{I_{A},R}^{i}$$
(129)

$$I_{C}^{i}(t+dt) \qquad \coloneqq I_{C}^{i}(t) + d_{E,I_{C}}^{i} - d_{I_{C,G_{D}}}^{i} - d_{I_{C,R}}^{i} - d_{I_{C,ICU_{pre}}}^{i} - d_{I_{C,ICU_{pre^{*}}}}^{i} - d_{I_{C,H_{R}}}^{i} - d_{$$

$$G_D^{i,1}(t+dt) := G_D^{i,1}(t) + d_{I_C,G_D}^i - d_{G_D,G_D}^i$$
(131)

$$G_D^{i,2}(t+dt) := G_D^{i,2}(t) + d_{G_D,G_D}^i - d_{G_D,D}^i$$
(132)

$$ICU_{pre}^{i}(t+dt) \qquad \coloneqq ICU_{pre}^{i}(t) + d_{I_{c}ICU_{pre}}^{i} - d_{I_{C}U_{pre},ICU_{W_{R}}}^{i} - d_{I_{C}U_{pre},ICU_{W_{D}}}^{i} - d_{I_{C}U_{pre},ICU_{W_{D}}}^{i} - d_{I_{C}U_{pre},ICU_{W_{D}}}^{i} - d_{I_{C}U_{pre},ICU_{W_{D}}}^{i} - d_{I_{C}U_{pre},ICU_{W_{D}}}^{i} - d_{I_{C}U_{pre},ICU_{D}}^{i} - d_{I_{C}U_{pre},ICU_{D^{*}}}^{i} - d_{I_{C}U_{pre},ICU_{W_{D}}}^{i} - d_{I_{C}U_{pre},ICU_{D^{*}}}^{i} - d_{I_{C}U_{pre},ICU_{W_{D}}}^{i} - d_{I_{C}U_{pre},ICU_{W_{D}}}^{i} - d_{I_{C}U_{pre},ICU_{D^{*}}}^{i} - d_{I_{C}U_{pre},ICU_$$

$$ICU_{pre^{*}}^{i}(t+dt) \coloneqq ICU_{pre^{*}}^{i}(t) + d_{I_{C,ICU}_{pre^{*}}}^{i} - d_{I_{CU}_{pre^{*}}ICU_{W_{p^{*}}}}^{i} - d_{I_{CU}_{pre^{*}},ICU_{W_{p^{*}}}}^{i} - d_{I_{CU}_{pre^{*}},ICU_{p^{*}}}^{i}$$
(134)

$$ICU_{W_{R}}^{i}(t+dt) \coloneqq ICU_{W_{R}}^{i}(t) + d_{ICU_{pre},ICU_{W_{R}}}^{i} - d_{ICU_{W_{R}},W_{R}}^{i} - d_{ICU_{W_{R}},ICU_{W_{R}^{*}}}^{i} - d_{ICU_{W_{R}},W_{R}^{*}}^{i}$$
(135)

$$ICU_{W_{R^{*}}}^{i}(t+dt) \coloneqq ICU_{W_{R^{*}}}^{i}(t) + d_{ICU_{pre^{*}},ICU_{W_{R^{*}}}}^{i} + d_{ICU_{W_{R^{*}}},ICU_{W_{R^{*}}}}^{i} + d_{ICU_{pre},ICU_{W_{R^{*}}}}^{i} - d_{ICU_{W_{R^{*}}},W_{R^{*}}}^{i}$$
(136)

$$ICU_{W_D}^{i}(t+dt) \coloneqq ICU_{W_D}^{i}(t) + d_{ICU_{pre},ICU_{W_D}}^{i} - d_{ICU_{W_D},W_D}^{i} - d_{ICU_{W_D},ICU_{W_D}}^{i} - d_{ICU_{W_D},W_D}^{i}$$
(137)

$$ICU_{W_{D^{*}}}^{i}(t+dt) \stackrel{\coloneqq}{=} ICU_{D^{*}}^{i}(t) + d_{ICU_{pre^{*},ICU_{W_{D^{*}}}}}^{i} + d_{ICU_{W_{D^{*}}}}^{i}lcu_{W_{D^{*}}}} + d_{ICU_{pre,ICU_{W_{D^{*}}}}}^{i} - (138)$$

$$ICU_{D^{*}}^{i}(t+dt) \stackrel{\coloneqq}{=} ICU_{D}^{i}(t) + d_{ICU_{pre,ICU_{D}}}^{i} - d_{ICU_{D,ICU_{D}}}^{i}lcu_{D^{*}}} - d_{ICU_{D,ICU_{D^{*}}}}^{i,1,2} - d_{ICU_{D,ICU_{D^{*}}}}^{i,1,2} - d_{ICU_{D,ICU_{D^{*}}}}^{i,1,2} - d_{ICU_{D,ICU_{D^{*}}}}^{i,1,2} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,2} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,2} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,2} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,2} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,1} - d_{ICU_{D^{*},ICU_{D^{*}}}}}^{i,1,1} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,1} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,1,1} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,1,1} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,1,1} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,1,1} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,1,1} - d_{ICU_{D^{*},ICU_{D^{*}}}}^{i,1,1,1} - d_{IC$$

$$W_R^{i,2}(t+dt) \coloneqq W_R^{i,2}(t) + d_{W_R,W_R}^i - d_{W_R,R}^i - d_{W_R,W_R^*}^{i,2,2}$$
(144)

$$W_{R^*}^{i,1}(t+dt) \coloneqq W_{R^*}^{i,1}(t) + d_{ICU_{W_{R^*},W_{R^*}}}^i + d_{W_{R,W_{R^*}}}^{i,1,1} + d_{ICU_{W_{R},W_{R^*}}}^i - d_{W_{R^*,W_{R^*}}}^i$$
(145)

$$W_{R^*}^{i,2}(t+dt) \coloneqq W_{R^*}^{i,2}(t) + d_{W_{R^*}W_{R^*}}^i + d_{W_{R}W_{R^*}}^{i,2,2} + d_{W_{R}W_{R^*}}^{i,1,2} - d_{W_{R^*}R}^i$$
(146)

$$W_{D}^{i}(t+dt) \coloneqq W_{D}^{i}(t) + d_{ICU_{W_{D}},W_{D}}^{i} - d_{W_{D},D}^{i} - d_{W_{D},W_{D}^{*}}^{i}$$
(147)

$$W_{D^*}^i(t+dt) \coloneqq W_{D^*}^i(t) + d_{I_{CU_{W_{D^*},W_{D^*}}}^i} + d_{W_{D,W_{D^*}}}^i + d_{I_{CU_{W_D},W_{D^*}}}^i - d_{W_{D^*,D}}^i$$
(148)

$$H_D^{i,1}(t+dt) \coloneqq H_D^{i,1}(t) + d_{I_C,H_D}^i - d_{H_D,H_D}^i - d_{H_D,H_D}^{i,1,1} - d_{H_D,H_D^*}^{i,1,2}$$
(149)

$$H_D^{i,2}(t+dt) := H_D^{i,2}(t) + d_{H_D,H_D}^i - d_{H_D,D}^i - d_{H_D,H_D}^{i,2,2}$$
(150)

$$H_{D^*}^{i,1}(t+dt) \coloneqq H_{D^*}^{i,1}(t) + d_{I_C,H_{D^*}}^i + d_{H_D,H_D^*}^{i,1,1} - d_{H_{D^*},H_{D^*}}^i$$
(151)

$$H_{D^*}^{i,2}(t+dt) \coloneqq H_{D^*}^{i,2}(t) + d_{H_{D^*},H_{D^*}}^i + d_{H_{D},H_{D}^*}^{i,2,2} + d_{H_{D},H_{D}^*}^{i,1,2} - d_{H_{D^*},D}^i$$
(152)

$$H_{R}^{i}(t+dt) \coloneqq H_{R}^{i}(t) + d_{I_{C},H_{R}}^{i} - d_{H_{R},R}^{i} - d_{H_{R},H_{R}}^{i}$$
(153)

$$H_{R^*}^i(t+dt) := H_{R^*}^i(t) + d_{I_C,H_R^*}^i + d_{H_R,H_R^*}^i - d_{H_R^*,R}^i$$
(154)

$$R^{i}(t+dt) \coloneqq R^{i}(t) + d^{i}_{I_{A},R} + d^{i}_{I_{C},R} + d^{i}_{H_{R},R} + d^{i}_{H_{R}^{*},R} + d^{i}_{W_{R},R} + d^{i}_{W_{R}^{*},R}$$
(155)

$$T_{sero_{pre}}^{i}(t+dt) \coloneqq T_{sero_{pre}}^{i}(t) + d_{E,I_{A}}^{i} + d_{E,I_{C}}^{i} - d_{T_{sero_{pre}},T_{sero_{pre}},T_{sero_{neg}}}^{i} - d_{T_{sero_{pre}},T_{sero_{neg}}}^{i}$$

$$(156)$$

$$T^{i}_{sero_{pos}}(t+dt) \coloneqq T^{i}_{sero_{pos}}(t) + d^{i}_{T_{sero_{pos}},T_{sero_{pos}}}$$
(157)

$$T_{sero_{neg}}^{i}(t+dt) \coloneqq T_{sero_{neg}}^{i}(t) + d_{T_{sero_{pre}},T_{sero_{neg}}}^{i}$$
(158)

$$T^{i}_{PCR_{pre}}(t+dt) \coloneqq T^{i}_{PCR_{pre}}(t) + d^{i}_{S,E} - d^{i}_{T_{PCR_{pre}},T_{PCR_{pos}}}$$
(159)

$$T^{i}_{PCR_{pos}}(t+dt) \coloneqq T^{i}_{PCR_{pos}}(t) + d^{i}_{T_{PCR_{pre}},T_{PCR_{pos}}} - d^{i}_{T_{PCR_{pos}},T_{PCR_{neg}}}$$
(160)

$$T^{i}_{PCR_{neg}}(t+dt) \coloneqq T^{i}_{PCR_{neg}}(t) + d^{i}_{T_{PCR_{pos}},T_{PCR_{neg}}}$$
(161)

357 1.7 Observation process

.

To describe the epidemic in each NHS region, we fitted our model to time series data on 358 hospital admissions, hospital ward occupancy (both in general beds and in ICU beds), 359 360 deaths in hospitals, deaths in care homes, population serological surveys and PCR testing data (section 1.1 and Table S 1). 361

362 1.7.1 Notation for distributions used in this section

363 If $Y \sim \text{NegBinom}(m, \kappa)$, then *Y* follows a negative binomial distribution with mean *m* and 364 shape κ , such that

365

$$P(Y = y) = \frac{\Gamma(\kappa + y)}{y! \Gamma(\kappa)} \left(\frac{\kappa}{\kappa + m}\right)^{\kappa} \left(\frac{m}{\kappa + m}\right)^{y}$$
(162)

366

367 where $\Gamma(x)$ is the gamma function. The variance of *Y* is $m + \frac{m^2}{\kappa}$.

368 If $Z \sim \text{BetaBinom}(n, \omega, \rho)$, then Z follows a beta-binomial distribution with size n, mean 369 probability ω and overdispersion parameter ρ , such that

370

$$P(Z=z) = {\binom{n}{z}} \frac{B(z+a,n-z+b)}{B(a,b)}$$
(163)

371

372 where
$$a = \omega\left(\frac{1-\rho}{\rho}\right)$$
, $b = (1-\omega)\left(\frac{1-\rho}{\rho}\right)$ and $B(a,b)$ is the beta function. The mean of *Z* is $n\omega$
373 and the variance is $n\omega(1-\omega)[1+(n-1)\rho]$.

374

375 1.7.2 Hospital admissions and new diagnoses in hospital

We represented the daily number of confirmed COVID-19 hospital admissions and new

diagnoses for existing hospitalised cases, $Y_{adm}(t)$, as the observed realisations of an

378 underlying hidden Markov process, $X_{adm}(t)$, defined as:

379

$$\coloneqq \sum_{i} \left(\sum_{j \in \{H_{R}^{*}, H_{D}^{*}, ICU_{pre}\}} d_{I_{C,j}}^{i} + \sum_{j \in \{H_{R}, ICU_{pre}, ICU_{W_{R}}, ICU_{W_{D}}, W_{D}\}} d_{j,j^{*}}^{i} \right) + d_{H_{D}, H_{D^{*}}}^{i,1,1} + d_{H_{D}, H_{D^{*}}}^{i,1,2} + X_{adm}(t) \quad d_{H_{D}, H_{D^{*}}}^{i,2,2} + d_{ICU_{D}, ICU_{D^{*}}}^{i,1,2} + d_{ICU_{D}, ICU_{D^{*}}}^{i,2,2} + d_{ICU_{D}, ICU_{D^{*}}}^{i,2,2} + d_{W_{R}, W_{R^{*}}}^{i,1,1} + d_{W_{R}, W_{R^{*}}}^{i,2,2} + d_{ICU_{D}, ICU_{D^{*}}}^{i,2,2} + d_{ICU_{W_{R^{*}}, W_{R^{*}}}^{i,2,2} + d_{ICU_{W_{R^{*}},$$

380

381 Which was related to the data via a reporting distribution:

382

$$Y_{adm}(t) \sim \text{NegBinom}(X_{adm}(t), \kappa_{adm})$$
 (165)

383

We allow for overdispersion in the observation process to account for noise in the underlying data streams, for example due to day-of-week effects on data collection. We adopt $\kappa = 2$ for all NHSE data streams, so that they contribute equal weight to the overall likelihood.

388 1.7.3 Hospital bed occupancy by confirmed COVID-19 cases

389 The model predicted general hospital bed occupancy by confirmed COVID-19 cases, 390 $X_{hosp}(t)$ as:

$$X_{hosp}(t) \coloneqq \sum_{i} \left(I_{H_{R}^{*}}^{i}(t) + I_{H_{D}^{*}}^{i}(t) + I_{ICU_{pre}^{*}}^{i}(t) + I_{W_{D}^{*}}^{i}(t) + I_{W_{R}^{*}}^{i}(t) \right)$$
(166)

391 Which was related to the observed daily general bed-occupancy via a reporting distribution:

$$Y_{hosp}(t) \sim \text{NegBinom}(X_{hosp}(t), \kappa_{hosp})$$
 (167)

392 with $\kappa_{hosp} = 2$ as above.

393

Similarly, the model predicted ICU bed occupancy by confirmed COVID-19 cases, $X_{ICU}(t)$ as:

$$X_{ICU}(t) := \sum_{i} \left(I^{i}_{ICU_{W_{R^{*}}}}(t) + I^{i}_{ICU_{W_{D^{*}}}}(t) + I^{i}_{ICU_{D^{*}}}(t) \right)$$
(168)

Which was related to the observed daily ICU bed-occupancy via a reporting distribution:

$$Y_{ICU}(t) \sim \text{NegBinom}(X_{ICU}(t), \kappa_{ICU})$$
(169)

398

399 with $\kappa_{ICU} = 2$.

400 1.7.4 Hospital and care homes COVID-19 deaths

401 The reported number of daily COVID-19 deaths in hospitals, $Y_{hosp_D}(t)$ was considered as 402 the observed realisation of an underlying hidden Markov process, $X_{hosp_D}(t)$, defined as:

$$X_{hosp_{D}}(t) := \sum_{i} \left(d^{i}_{H_{D},D} + d^{i}_{H^{*}_{D},D} + d^{i}_{ICU_{D},D} + d^{i}_{ICU^{*}_{D},D} + d^{i}_{W_{D},D} + d^{i}_{W^{*}_{D},D} \right)$$
(170)

403

404 Which was related to the data via a reporting distribution:

$$Y_{hosp_D}(t) \sim \text{NegBinom}\left(X_{hosp_D}(t), \kappa_{hosp_D}\right)$$
 (171)

405 with $\kappa_{hosp_D} = 2$.

406 Similarly, we represented the reported number of daily COVID-19 deaths in care homes,

407 $Y_{G_D}(t)$, as the observed realisations of an underlying hidden Markov process, $X_{G_D}(t)$, defined 408 as:

$$X_{G_D}(t) := d_{G_D,D}^{CHR}$$
(172)

409 Which was related to the data via a reporting distribution:

$$Y_{G_D}(t) \sim \text{NegBinom}\left(X_{G_D}(t), \kappa_{G_D}\right)$$
(173)

410 with $\kappa_{G_D} = 2$.

411

412 1.7.5 Serosurveys

We model serological testing of all individuals aged 15-65, and define the resulting number
of seropositive and seronegative individuals (were all individuals aged 15-65 to be tested),
as:

$$X_{sero_{pos}}(t) := \sum_{i=[15,20)}^{[60,65]} T_{sero_{pos}}^i(t)$$
(174)

$$X_{sero_{neg}}(t) := \left(\sum_{i=[15,20)}^{[60,65)} N^i\right) - X_{sero_{pos}}(t)$$
(175)

417 We compared the observed number of seropositive results, $Y_{sero_{pos}}(t)$, with that predicted by

418 our model, allowing for i) the sample size of each serological survey, $Y_{sero_{pos}}(t)$ and ii)

419 imperfect sensitivity ($p_{sero_{sens}}$) and specificity ($p_{sero_{snec}}$) of the serological assay:

$$Y_{sero_{pos}}(t) \sim \text{Binom}\left(Y_{sero_{test}}(t), \omega_{sero_{pos}}(t)\right)$$
 (176)

420 Where:

$$\omega_{sero_{pos}}(t) := \frac{p_{sero_{sens}} X_{sero_{pos}}(t) + \left(1 - p_{sero_{spec}}\right) X_{sero_{neg}}(t)}{X_{sero_{pos}}(t) + X_{sero_{neg}}(t)}$$
(177)

421

422 1.7.6 *PCR testing*

423 As described in the data section (1.1), we fitted the model to PCR testing data from two 424 separate sources:

pillar 2: the government testing programme, which recommends that individuals with
 COVID-19 symptoms are tested (34),

the REACT-1 study, which aims to quantify the prevalence of SARS-CoV-2 in a random sample of the England population on an ongoing basis (35).

429

We only use Pillar 2 PCR test results for individuals aged 25 and over (we assume this
includes all care home workers and residents). We assume that individuals who get tested
through Pillar 2 PCR testing are either newly symptomatic SARS-CoV-2 cases (who will test
positive):

$$X_{P2_{pos}}(t) := \sum_{i=[25,30)}^{CHW} d_{E,I_C}^i$$
(178)

434

435 or non-SARS-CoV-2 cases who have symptoms consistent with COVID-19 (who will test436 negative):

$$X_{P2_{neg}}(t) := p_{NC}\left(\left(\sum_{i=[25,30)}^{CHW} N^{i}\right) - X_{P2_{pos}}(t)\right)$$
(179)

437

438 where p_{NC} is the probability of non SARS-CoV-2 cases having symptoms consistent with 439 COVID-19 leading them to seek a PCR test.

- 441 We compared the observed number of positive PCR tests, $Y_{P2_{pos}}(t)$ with that predicted by
- 442 our model, accounting for the number of PCR tests conducted each day under pillar 2,
- 443 $Y_{P2_{test}}(t)$, by calculating the probability of a positive PCR result (assuming perfect sensitivity
- 444 and specificity of the PCR test):

$$\omega_{P2_{pos}}(t) := \left(X_{P2_{pos}}(t) \right) / \left(X_{P2_{pos}}(t) + X_{P2_{neg}}(t) \right)$$
(180)

446 People may seek PCR tests for many reasons and thus the pillar 2 data are subject to 447 competing biases. We therefore allowed for an over-dispersion parameter $\rho_{P2_{test}}$, which we 448 fitted separately for each region in the modelling framework:

$$Y_{P2_{pos}}(t) \sim \text{BetaBinom}\left(Y_{P2_{test}}(t), \omega_{P2_{pos}}(t), \rho_{P2_{test}}\right)$$
(181)

449

450 We incorporated the REACT-1 PCR testing data into the likelihood analogously to the 451 serology data, by considering the model-predicted number of PCR-positives $X_{R1_{pos}}(t)$ and 452 PCR-negatives $X_{R1_{neg}}(t)$, were all individuals aged over five and not resident in a care home 453 to be tested:

454

$$X_{R1_{pos}}(t) := \sum_{i=[5,10),\dots,[80+),CHW} T^{i}_{PCR_{pos}}(t)$$
(182)

$$X_{R1_{neg}}(t) \coloneqq \sum_{i=[5,10],\dots,[80+),CHW} N^{i}(t) - X_{R1_{pos}}(t)$$
 (183)

455

456 We compared the daily number of positive results observed in REACT-1, $Y_{R1_{pos}}(t)$, given the 457 number of people tested on that day, $Y_{R1_{test}}(t)$, to our model predictions, by calculating the 458 probability of a positive result, assuming perfect sensitivity and specificity of the REACT-1 459 assay:

$$\omega_{R_{1_{pos}}}(t) := \left(X_{R_{1_{pos}}}(t)\right) / \left(X_{R_{1_{pos}}}(t) + X_{R_{1_{neg}}}(t)\right)$$
(184)

460

$$Y_{R_{1}_{pos}}(t) \sim \text{Binom}\left(Y_{R_{1}_{test}}(t), \omega_{R_{1}_{pos}}(t)\right)$$
(185)

461

The overall likelihood function was then calculated as the product of the likelihoods of the individual observations.

464

465 **1.8 Bayesian inference and model fitting**

A closed-form expression of the likelihood of the observed data given the model and its
parameters was not analytically tractable, so we used particle filtering methods to obtain an
unbiased estimate of the likelihood which can be efficiently sampled from (36). Where
appropriate, we used estimates from the literature to set model parameters at fixed values.
We limited the parameters being inferred to just those with particular epidemiological
interest, or with large uncertainty in existing literature.

472

The model was fitted independently to each NHS region. For each NHS region, we aimed to infer the values of 26 model parameters:

• the local epidemic start-date, t_0 ;

476	• thirteen transmission rates at different time points $\beta_1, \dots, \beta_{12}$;
477 478	 three parameters governing transmission to and within care homes m_{CHW}, m_{CHR}, ε;
479 480	• the probability of symptomatic individuals developing serious disease requiring hospitalisation, p_H^{max} , for the group with the largest probability;
481 482	• the probability of a care home resident dying in a care home if they have severe disease requiring hospitalisation, $p_{G_D}^{CHR}$;
483 484	• the probability, at the start of the pandemic, of a patient being admitted to ICU after hospitalisation, p_{ICU}^{max} , for the group with the largest probability;
485 486 487	• the probabilities, at the start of the pandemic, of dying in a hospital general ward, $p_{H_D}^{max}$, in the ICU, $p_{ICU_D}^{max}$, and in a stepdown ward following ICU, $p_{W_D}^{max}$, for the groups with the largest probability;
488	• the multiplier for hospital mortality after improvement in care, μ_H ;
489 490	 the multiplier for probability of admission to ICU after improvement in care, μ_{ICU};
491 492 493	• the daily proportion p_{NC} , of the population seeking to get tested for an infection of SARS-Cov-2 following COVID-19 like symptoms and the overdispersion of the corresponding observation distribution $\rho_{P2_{test}}$.
494	
495 496 497 498 499 500 501 502 503 504 505	We used particle Monte Carlo Markov Chain (pMCMC) methods (37), implementing a particle marginal Metropolis-Hastings algorithm with a bootstrap particle filter (38) with 96 particles (for sufficient variance in likelihood and a convenient multiple of number of available CPU cores for efficiency), to obtain a sample from the posterior distribution of the model parameters given the observed data. If the expected values of count distributions are zero when observed values are non-zero, this results in particles of zero weight, which can lead to the particle filter estimating the marginal likelihood to be 0. Therefore, to get a small but non-zero weight for each particle at every observation, within our particle filter likelihood we add a small amount of noise (exponentially distributed with mean 10^{-6}) to count values from the model.

- 506 Within our particle filter we add small amounts of exponentially-distributed noise (with mean 507 10^{-6}) to model outputs prior to calculating likelihood weights to avoid particles of zero 508 weight, instead resulting in small but non-zero weights.
- 509 We implemented our model and parameter inference in an R package, *sircovid* (39),
- 510 available at <u>https://mrc-ide.github.io/sircovid</u>, which uses two further R packages, *dust* to run
- 511 the model in efficient compiled code and *mcstate* to implement the pMCMC sampler using
- 512 Metropolis-Hastings sampling (40).
- 513 At each iteration, the sampler proposes an update to the joint distribution of parameters.
- 514 These proposals are generated from multivariate Gaussian densities centred on the current
- 515 parameter values, and with a covariance structure chosen to facilitate efficient mixing of the
- 516 Markov chain. We specified reflecting boundaries for the proposal kernel to ensure that the
- 517 proposed parameters are both epidemiologically and mathematically plausible and retain
- 518 symmetry in the proposals.
- 519 For each regional fit, eight parallel chains of the pMCMC were run for 11,000 iterations, with 520 the first 1,000 discarded as burn-in, and a 1/80 thinning. We assessed convergence visually.

522 **1.9 Prior distributions and parameter calibration**

523 1.9.1 Risk of hospital admission

In our Bayesian inference framework, we estimate p_H^{max} , the probability of hospital admission for symptomatic cases in the group (across all ages and CHW and CHR) with the largest probability of hospital admission. However, we fix the relative probability of hospital admission for the other age groups, ψ_H^i , defined so that $p_H^i = p_H^{max} \psi_H^i$, with $\psi_H^i = 1$ in the group with largest probability of hospital admission.

529 In this section we explain how the values of ψ_H^i were chosen. We used two sources of 530 information, an individual-level and an aggregated dataset. On the one hand, the COVID-19 531 Hospitalisation in England Surveillance System (CHESS) is a daily, confidential line list 532 containing highly detailed information on patients admitted to hospital with confirmed 533 COVID-19 (see following section 1.9.2 for further details). On the other hand, the 534 Government's Coronavirus Dashboard is an aggregated, publicly available situation report

535 updated daily. Amongst other data, it provides updates on the number of daily admissions

- and hospital occupancy by devolved nation and, for England, by NHS region. We found the
- 537 demography of hospitalisation in CHESS to be biased toward older patients compared to
- 538 Dashboard data (Figure S3). We thus undertook a two-step approach to infer the
- 539 demographic composition of COVID-19 hospitalisations across England.
- 540 Firstly, we derived an initial approximation of ψ_H^i by dividing the total number of hospital 541 admissions for age group *i* in CHESS over the total number of positive PCR tests (Pillar 2) 542 for *i*. Both data sources were censored to include patients admitted to hospital or with a 543 specimen data (i.e. the date the test was taken), respectively, between March 1 and
- 545 Specifien data (i.e. the date the test was taken), respectively, between March 1 and 544 December 2, 2020. We ran our full inference framework using this initial approximation
- for ψ_H^i and observed its fit to the demographic composition of admissions from the data.
- 546 As a second step, we refined our initial approximations of ψ_{H}^{i} over a series of iterations of
- 547 our inference framework, by drawing the modelled $(p_{H_{Model}}^{i})$ and observed $(p_{H_{Dashboard}}^{i})$
- 548 proportion of admissions for each age group (i.e. admissions in age group i divided by all
- admissions) and using it to derive a re-scaling factor for a new proposal for ψ_H^i as follows:
- 550

$$New \psi_{H}^{i} = Initial \psi_{H}^{i} * \frac{p_{HDashboard}^{i}}{p_{HModel}^{i}}$$
(186)

551

552 This process was repeated to obtain a close approximation to the observed proportion of 553 admissions by age and region (Figure S3). A key strength of our approach is that we did not 554 overfitted demography by individual regions. Rather, by assuming ψ_H^i to be independent of 555 geographic region, we allowed our inference framework to derive the number of admissions 556 for each five-year age band *i* solely based on ψ_H^i , the demographic composition of the NHS 557 region and inferred epidemic parameters, such as R_t .



Figure S 3: Proportion of admissions by age. a) Comparison of model outputs to data from the
Government's Coronavirus Dashboard, aggregated to five broad age categories. b) Age spline fitted
(red) to Government's Coronavirus Dashboard, with age categories disaggregated to five-year bands.
The fitted spline (red) was used as input parameters for the probability of hospitalisation by age.

563

564 1.9.2 Severity and hospital progression

565 We also performed extensive preliminary analysis to inform the age-structure of progression 566 parameters within hospital. Data from the COVID-19 Hospitalisation in England Surveillance 567 System (CHESS) were used to fit a simple model of patient clinical progression in hospital. 568 The model structure was designed to mirror the within-hospital component of the wider 569 mechanistic transmission model, but without the complexities arising from unknown 570 admission dates and with greater detail on trends with age (Figure S 4).



573 Figure S 4: Directed Acyclic Graph of the hospital pathways fitted to CHESS data, which mirror the 574 model structure described in Figure S 2, but with all parameters varying with age and not over time.

575

576 CHESS data consists of a line list of daily individual patient-level data on COVID-19 infection 577 in persons requiring hospitalisation, including demographic and clinical information on 578 severity and outcomes. Data were filtered to patients admitted between 18th March and 31st May 2020 (inclusive), with subsequent progression events possible up until 25th Nov 2020. 579 This gave >5 months for outcomes to complete, and hence justified filtering to patients with 580 resolved outcomes only. The length of stay in each state was taken as the difference 581 582 between the registered dates of entering and leaving each hospital ward. Lengths of stay 583 were assumed to follow Erlang distributions, as in the wider model, with a distinct mean and shape parameter for each state. Specifically, the probability of being in state $X \in$ 584 $\{pre, H_D, H_R, ICU_D, ICU_{W_R}, ICU_{W_D}, W_R, W_D\}$ for $n \in \mathbb{N}_0$ days was taken as the integral over day 585 586 *n* of the Erlang distribution with mean m_x and shape s_x :

587

$$\Pr(\text{in state } X \text{ for } n \text{ days}) = \int_{n}^{n+1} \frac{\left(\frac{S_X}{m_X}\right)^{S_X} t^{S_X - 1} e^{\frac{-S_X t}{m_X}}}{(s_X - 1)!} dt.$$
(187)

588

For a patient of age *a*, this was combined with the probability of their path through the hospital progression model, taken as the product of the individual transition probabilities at each bifurcation, i.e. values taken from $p_Z(a)$ for $Z \in \{ICU, H_D, ICU_D, W_D\}$. Transition probabilities were modelled as functions of age using logistic-transformed cubic splines.

- 593 Knots were defined at coordinates $[x^i, y_Z^i]$, where x^i values were fixed at
- 594 $\{0, 20, 40, 60, 80, 100, 120\}$ and y_Z^i were free parameters to be estimated. The complete
- spline, $y_Z(a)$ for $a \in 0:120$, was obtained from these knots using standard expressions for cubic spline interpolation. Finally, transition probabilities were obtained from the raw $y_Z(a)$
- 597 values using the logistic transformation: $p_Z(a) = 1/(1 + e^{-y_Z(a)})$.

598 In total there were 44 free parameters in the within-hospital progression model: 8 mean 599 length of stay parameters, 8 length of stay shape parameters and 4×7 transition probability 600 spline nodes (Figure S 4, Table S 4).

601

Table S 4: Descriptions of all states and transitions in the simplified hospital progression model fitted
 to CHESS data.

State (X)	Description
pre	General admission before step-up to ICU
H _D	General ward before death in general ward
H_R	General ward before discharge from general ward
ICU _D	ICU before death in ICU
ICU _{WD}	ICU before step-down and eventual death in step-down care
ICU _{WR}	ICU before step-down and eventual discharge from step- down care
W _D	Step-down (general) ward before death
W _R	Step-down (general) ward before discharge
Transition (Z)	Description
ICU	Admission to ICU from general ward
H_D	Death in general ward
ICU _D	Death in ICU
W _D	Death in step-down care

604

605 All parameters of the hospital progression model were given priors (Table S 5) and 606 estimated within a Bayesian framework. All length of stay parameters were given uniform priors over a plausible range of values. For transition probabilities, the first spline node y_{z}^{1} 607 608 was given a prior that corresponded to a uniform distribution after logistic transformation, 609 and subsequent spline nodes were given a multivariate normal prior to apply a smoothing 610 constraint to the spline. Parameters were estimated jointly via MCMC using the custom package markovid v1.5.0 (41), which uses the random-walk Metropolis-Hastings algorithm to 611 612 draw from the joint posterior distribution. MCMC was run for 1000 burn-in iterations and 613 100,000 sampling iterations replicated over 10 independent chains. Convergence was 614 assessed via the Gelman-Rubin diagnostic (all parameters had potential scale reduction 615 factor <1.1) and sampling sufficiency was assessed by visualising posterior distributions and 616 by effective sample size (ESS) calculations (all parameters had ESS >100,000). Table S 5: Priors on all length of stay distributions and transition probability splines. $Uniform_{cont}(a, b)$ 617

- Table S 5: Priors on all length of stay distributions and transition probability splines. $Uniform_{cont}(a, b)$ denotes the continuous uniform distribution, and $Uniform_{disc}(a, b)$ the discrete uniform distribution
- 619 *between a and b (inclusive).*

Parameter	Description	Prior
$m_X = \frac{1}{\gamma_X}$	Mean of Erlang length of stay distribution	$m_X \sim \text{Uniform}_{\text{cont}}(0,20)$

k _X	Shape parameter of Erlang length of stay distribution	$k_X \sim \text{Uniform}_{\text{disc}}(1,10)$
y_Z^1	First spline node of (transformed) transition probability	$f(y_Z^1) \propto \frac{e^{-y_Z^1}}{(1+e^{-y_Z^1})^2}$, for $y_Z^! \in (-10, 10)$
y_Z^j for $j \in 2:7$	Subsequent spline nodes of (transformed) transition probability	$y_Z^j \sim \operatorname{Normal}(y_Z^{j-1}, 0.25)$

621 Parameter estimates (posterior medians) were passed to the wider mechanistic transmission 622 model as fixed values (Figure S 5). For transition probabilities, the full age-spline (Figure 3, 623 main text) was aggregated to 5-year age groups and normalised by the largest value to define the relative risk with age. The absolute risk in the mechanistic transmission model 624 625 was obtained by multiplying the relative risk by region-specific scaling factors that were fitted 626 as free parameters in the pMCMC. Hence, the preliminary analysis of CHESS data was 627 used to inform trends of severity with age, but not the absolute probability of progression 628 through the hospital states, which was informed by the Government's Coronavirus 629 Dashboard data.

630 For the wider mechanistic transmission model, we used Beta distributions for the priors of the various fitted probabilities regarding hospitalisation. The priors for p_{ICU}^{max} , $p_{H_D}^{max}$, $p_{ICU_D}^{max}$ and 631 $p_{W_{D}}^{max}$ were all informed by the fitting to CHESS data by taking the median fitted value for the 632 prior mean, which we halve in the case of p_{ICU}^{max} to account for CHESS being biased to more 633 severe patients. The prior distributions are then calibrated so that the lower bound of the 634 95% confidence interval is 0.1 lower than the prior mean. For p_{H}^{max} and $p_{G_{D}}^{CHR}$, we assume 635 prior means of 0.75 and calibrate the prior so that the lower bound of the 95% confidence 636 637 interval is 0.2 lower than the mean. For the multipliers for hospital mortality after 638 improvement in care, μ_H , and for probability of admission to ICU after improvement in care, 639 μ_{ICU} , we used uninformative U[0,1] priors. 640

641

Length of stay in each hospital state



643 644

Figure S 5: Posterior 95% credible intervals of length of stay mean (left) and shape parameters (right).

645

646 1.9.3 Serosurveys

To keep serology parameters consistent between all regions we used estimates from the literature to fix the parameters of the seroconversion process. An alternative would have been to use these estimates as priors within a hierarchical model where some parameters would be shared between regions, but this would be much more involved computationally.

- 651 652 As described in section 1.3.2, the time to seroconversion from leaving the E^i compartment is 653 modelled by an exponential distribution time spent in $T^i_{sero_{pre}}$ with a proportion $p_{sero_{pos}}$
- 654 ultimately seroconverting and moving to $T_{sero_{pos}}^{i}$ and the remaining staying negative and
- 655 moving to $T_{sero_{neg}}^i$.
- 656

657 We fixed $p_{sero_{pos}}$ to 0.85 based on the estimate of 85% of infections becoming detectably 658 seropositive with the EUROIMMUN assay used in the NHSBT serological surveys (42). The 659 specificity of the serology test $p_{sero_{spec}}$ is fixed to 0.99 also from (42). Finally, the sensitivity of 660 serology test $p_{sero_{sens}}$ is assumed to be 1 as it is non-distinguishable from the time varying 661 seroconversion process (Table S7).

- 662
- 663 1.9.4 PCR positivity

664 As for other compartments, we modelled the duration of SARS-CoV-2 PCR-positivity after 665 symptom onset using an Erlang distribution $\tau \sim \text{Erlang}(k, \gamma)$, with k successive compartments 666 and a total mean time spent of $\frac{k}{\gamma}$ and variance $\frac{k}{\gamma^2}$.

667 We estimated the parameters of this distribution from Omar et al. (16), which reported the 668 cumulative distribution of duration of PCR positivity in 523 individuals with mild COVID-19 669 disease in home quarantine in a German region. We performed a survival analysis using a 670 gamma-accelerated failure time model fitted to their data, from which we estimated the 671 mean and variance of the time from symptom onset to PCR negativity. This was used to 672 derive values of k and γ shown in Table S 2.

- 673 1.9.5 Local start date of the epidemic
- The start date of the epidemic for each region is assumed to have a uniform prior on the dates from 1st January 2020 to 15th March 2020, inclusive – with the latter date
- 676 corresponding to the last date before the data begin.

677 1.9.6 Time-varying transmission rates

678 We set priors for the transmission rates $\beta_1, ..., \beta_{12}$ to reflect a Gamma distribution for the 679 reproduction number R_t with a reasonable 95% confidence interval a priori. To obtain a prior for the corresponding β_k , we then scale by a factor of 0.0241 (given other parameter values, 680 681 $\beta_k = 0.0241$ would correspond approximately to $R_t = 1$). The 95% ranges for R_0 we used 682 are (i) (2.5, 3.5) at the onset of the epidemic (corresponding to β_1); and then R_t (ii) (0.4, 3.5) 683 at announcement of the first lockdown (corresponding to β_2); and (iii) (0.4, 3) from the 684 implementation of the first lockdown onwards (corresponding to $\beta_3, \dots, \beta_{12}$). The values are 685 consistent with the values of the COMIX study (43).

686 1.9.7 Transmission within care homes

687 For the transmission between care home workers and residents, m_{CHW} , and transmission 688 among care home residents, m_{CHR} , we used a prior distributions reflecting that these are 689 person-to-person infectious contact rates and thus should be scaled according to regional

690 care home demography. We then used a Gamma distribution with shape 5 and mean $\frac{0.1}{N^{CHR}}$

- for both of these parameters (recall that we assume there is a 1-to-1 ratio of care home workers to residents in each region, so $N^{CHW} = N^{CHR}$).
- For the parameter governing the reduction in contacts between the general population and care home residents, ϵ , we used an uninformative U[0,1] prior.
- 695 1.9.8 Parameters relating to Pillar 2 testing
- 696 For both the parameters p_{NC} and $\rho_{P2_{test}}$, we used uninformative U[0,1] priors.

Table S 6: Inferred model parameter notations, prior and posterior distributions. Note that $\Gamma(a, b)$ here refers to a Gamma distribution with shape a and scale b (such that the mean is ab), and B(a, b) refers to a Beta distribution with shape parameters a and b (such that the mean is a/(a + b)).

	Description	Group scaling	Prior	Mean (95% Cl)	Posterior NW**	Mean (95% Crl) NEY	MID	EE	LON	SW	SE
	Start date of regional	-	U[01/01,15		29-01	03-02	24-01	06-02	08-01	12-02	27-01
ι ₀	outbreak <i>(dd/mm/2020)</i>	-	/03]	-	(13/01, 07/02)	(29/01, 09/02)	(12/01, 02/02)	(30/01, 14/02)	(02/01, 20/01)	(09/02, 17/02)	(20/01, 04/02)
	Transmission rate (pp)										
$\boldsymbol{\beta}(\mathbf{t})$	eta_1	-	Г(136,0.0006)	0.07 (0.06, 0.08)	0.08 (0.06, 0.09)	0.08 (0.07, 0.09)	0.08 (0.07, 0.09)	0.08 (0.08, 0.09)	0.06 (0.06, 0.07)	0.09 (0.08, 0.09)	0.08 (0.07, 0.09)
	eta_2	-	Г(21.9,0.0026)	0.06 (0.04, 0.08)	0.09 (0.06, 0.11)	0.08 (0.05, 0.1)	0.07 (0.05, 0.09)	0.06 (0.04, 0.07)	0.04 (0.03, 0.06)	0.07 (0.04, 0.09)	0.05 (0.03, 0.06)
	eta_3	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.01 (0.01, 0.02)	0.02 (0.02, 0.02)	0.01 (0.01, 0.01)	0.02 (0.02, 0.02)	0.01 (0.01, 0.01)	0.02 (0.01, 0.02)	0.01 (0.01, 0.01)
	eta_4	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.02 (0.02, 0.02)	0.02 (0.01, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.01, 0.02)
	eta_5	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.02 (0.01, 0.02)	0.02 (0.02, 0.02)
	eta_6	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.02 (0.02, 0.03)	0.02 (0.01, 0.02)	0.02 (0.01, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)
	eta_7	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.03 (0.02, 0.03)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)
	eta_8	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.05 (0.04, 0.05)	0.04 (0.04, 0.05)	0.05 (0.04, 0.05)	0.04 (0.03, 0.04)	0.04 (0.04, 0.05)	0.03 (0.02, 0.04)	0.04 (0.03, 0.05)
	eta_9	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.04 (0.04, 0.05)	0.04 (0.04, 0.04)	0.04 (0.03, 0.04)	0.04 (0.03, 0.04)	0.04 (0.03, 0.04)	0.04 (0.04, 0.05)	0.03 (0.03, 0.04)
	eta_{10}	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.03 (0.03, 0.03)	0.03 (0.03, 0.04)	0.04 (0.04, 0.04)	0.04 (0.03, 0.04)	0.04 (0.04, 0.04)	0.04 (0.03, 0.04)	0.04 (0.04, 0.04)
	eta_{11}	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.02 (0.02, 0.02)	0.03 (0.02, 0.03)	0.03 (0.02, 0.03)	0.03 (0.02, 0.03)	0.03 (0.02, 0.03)	0.03 (0.02, 0.03)	0.03 (0.03, 0.03)
	β_{12}	-	Г(4.25,0.0079)	0.03 (0.01, 0.07)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.03 (0.03, 0.03)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)
ε	Relative reduction in contacts between CHR and the general population	-	<i>U</i> [0,1]	0.5 (0.03, 0.98)	0.43 (0.03, 0.95)	0.75 (0.51, 0.98)	0.77 (0.37, 0.97)	0.79 (0.51, 0.96)	0.28 (0.03, 0.49)	0.82 (0.74, 0.91)	0.89 (0.77, 0.99)
	•••		Pagianal		$\Gamma(5, 4.3 \times 10^{-7})$	$\Gamma(5, 3.7 \times 10^{-7})$	$\Gamma(5, 2.9 \times 10^{-7})$	$\Gamma(5, 5.2 \times 10^{-7})$	$\Gamma(5, 7.6 \times 10^{-7})$	$\Gamma(5, 4.9 \times 10^{-7})$	$\Gamma(5, 3.1 \times 10^{-7})$
	Transmission	-	Prior		2.2×10^{-6} (7.0 \times	$1.8 imes 10^{-6}$ (5.9 $ imes$	1.5×10^{-6} (4.7 \times	$2.6 imes 10^{-6}$ (8.4 $ imes$	3.8×10^{-6} (1.2 \times	$2.5 imes 10^{-6}$ (8.0 $ imes$	1.6×10^{-6} (5.1 ×
manu	hetween care home		1 1101		10^{-7} , 4.4×10^{-6})	10^{-7} , 3.7×10^{-6})	10^{-7} , 2.9 × 10^{-6})	10^{-7} , 5.3×10^{-6})	10^{-6} , 7.8 × 10^{-6})	10^{-7} , 5.0×10^{-6})	10^{-7} , 3.2×10^{-6})
III CHW	residents and staff				2.1e-06	1.7e-06	1.5e-06	2.7e-06	3.8e-06	1.8e-06	1.5e-06
		Posterior:		(1.4e-06, 2.7e-	(1.3e-06, 2.2e-	(1.1e-06, 1.9e-	(2.1e-06, 3.1e-	(3.1e-06, 4.7e-	(1.3e-06, 2.2e-	(1.1e-06, 1.8e-	
					06)	06)	06)	06)	06)	06)	06)

		Pagianal			$\Gamma(5, 4.3 \times 10^{-7})$	$\Gamma(5, 3.7 \times 10^{-7})$	$\Gamma(5, 2.9 \times 10^{-7})$	$\Gamma(5, 5.2 \times 10^{-7})$	$\Gamma(5, 7.6 \times 10^{-7})$	$\Gamma(5, 4.9 \times 10^{-7})$	$\Gamma(5, 3.1 \times 10^{-7})$
	Transmission rate m _{CHR} among care home	-	- Regional		2.2×10^{-6} (7.0 \times	1.8 × 10 ⁻⁶ (5.9 ×	1.5×10^{-6} (4.7 \times	2.6×10^{-6} (8.4 ×	3.8×10^{-6} (1.2 ×	2.5×10^{-6} (8.0 \times	1.6×10^{-6} (5.1 ×
m_{CHR}			FIIUI		10^{-7} , 4.4×10^{-6})	10^{-7} , 3.7×10^{-6})	10^{-7} , 2.9×10^{-6})	10^{-7} , 5.3 × 10^{-6})	10^{-6} , 7.8 × 10^{-6})	10^{-7} , 5.0 × 10^{-6})	10^{-7} , 3.2×10^{-6})
	residents		Destadiem		2.2e-06	2.5e-06 (1.4e-	1.6e-06 (7e-07,	3.4e-06 (2.1e-	2.8e-06 (5e-07,	4.2e-06 (3.8e-	3.3e-06 (2.9e-
			Posterior:		(1e-06, 3.4e-06)	06, 3.6e-06)	2.4e-06)	06, 4.3e-06)	4.8e-06)	06, 4.6e-06)	06, 3.6e-06)
	Probability of				· · ·	·			·		
p_H^{max}	hospitalisation if	$\psi^i_{\scriptscriptstyle H}$	B(15.8, 5.28)	0.75 (0.55, 0.91)	0.87 (0.8, 0.92)	0.9 (0.85, 0.94)	0.89 (0.83, 0.95)	0.78 (0.73, 0.84)	0.85 (0.79, 0.9)	0.86 (0.81, 0.93)	0.73 (0.68, 0.79)
	symptomatic	7 11	. ,	. ,	, ,						
	Probability of death in										
$p_{G_D}^{max}$	care home if requiring	$\psi^i_{G_D}$	B(15.8, 5.28)	0.75 (0.55, 0.91)	0.66 (0.37, 0.85)	0.77 (0.64, 0.88)	0.53 (0.41, 0.69)	0.58 (0.52, 0.63)	0.66 (0.5, 0.91)	0.64 (0.6, 0.69)	0.36 (0.32, 0.43)
-	hospitalisation	2									
	Probability of triage to										
p_{ICU}^{max}	ICU for new hospital	ψ^i_{ICU}	B(13.9, 43.9)	0.24 (0.14, 0.36)	0.15 (0.11, 0.18)	0.15 (0.11, 0.18)	0.17 (0.13, 0.21)	0.25 (0.21, 0.31)	0.31 (0.26, 0.37)	0.12 (0.11, 0.13)	0.23 (0.2, 0.25)
	admissions										
	Initial probability of										
$p_{H_D}^{max}$	death for general	$\psi^i_{H_D}$	B(42.1, 50.1)	0.46 (0.36, 0.56)	0.42 (0.35, 0.5)	0.46 (0.39, 0.53)	0.43 (0.38, 0.47)	0.47 (0.44, 0.51)	0.37 (0.32, 0.46)	0.5 (0.47, 0.53)	0.41 (0.35, 0.46)
	inpatients										
n ^{max}	Initial probability of	1/1 ⁱ	B(60.2 20.3)	0 67 (0 57 0 77)	0.66 (0.6, 0.72)	0 71 (0 66 0 77)	0 69 (0 58 0 77)	0 69 (0 62 0 75)	0.61 (0.51, 0.69)	0 71 (0 64 0 77)	0.63 (0.54, 0.75)
PICUD	death for ICU inpatients	Ψ_{ICU_D} B(00.2, 29		0.07 (0.07, 0.77)	0.00 (0.0, 0.72)	0.71 (0.00, 0.77)	0.03 (0.30, 0.17)	0.03 (0.02, 0.73)	0.01 (0.31, 0.09)	0.71 (0.64, 0.77)	0.03 (0.54, 0.75)
	Initial probability of										
$p_{W_D}^{max}$	death for stepdown	$\psi^i_{W_D}$	B(28.7, 52.1)	0.35 (0.25, 0.46)	0.35 (0.25, 0.46)	0.35 (0.3, 0.4)	0.36 (0.3, 0.5)	0.37 (0.3, 0.43)	0.34 (0.24, 0.43)	0.51 (0.44, 0.59)	0.37 (0.29, 0.45)
	inpatients										
	ICU admission multiplier										
μ_{ICU}	after improvement in	-	U[0,1]	0.5 (0.03, 0.98)	0.79 (0.59, 0.93)	0.76 (0.62, 0.93)	0.72 (0.56, 0.94)	0.51 (0.37, 0.64)	0.62 (0.51, 0.75)	0.83 (0.73, 0.99)	0.44 (0.3, 0.54)
	care										
	Hospital mortality										
μ_D	multiplier after	-	U[0,1]	0.5 (0.03, 0.98)	0.58 (0.45, 0.69)	0.47 (0.41, 0.53)	0.49 (0.42, 0.61)	0.47 (0.42, 0.56)	0.32 (0.27, 0.38)	0.35 (0.28, 0.43)	0.53 (0.44, 0.63)
	improvement in care										
	Prevalence of non-										
p_{NC}	COVID symptomatic	-	U[0,1]	0.5 (0.03, 0.98)	0.0031 (0.0029,	0.0022 (0.0021,	0.0025 (0.0023,	0.0028 (0.0026,	0.0028 (0.0027,	0.0019 (0.0018,	0.003 (0.0028,
	leading to test				0.0033)	0.0024)	0.0027)	0.0031)	0.003)	0.002)	0.0031)
0.00	Overdispersion of PCR	_	<i>U</i> [0 1]	0.5 (0.03 0.98)	0.0052 (0.0042,	0.0076 (0.0064,	0.0072 (0.0058,	0.0033 (0.0029,	0.0026 (0.0021,	0.0091 (0.0079,	0.0032 (0.0027,
PP2 _{test}	positivity		0[0,1]	0.0 (0.00, 0.90)	0.0062)	0.0086)	0.0088)	0.0037)	0.0031)	0.0103)	0.0037)
700	1										

Age-specific scaling factors for each parameter are set out in Table S 8.** Region codes: NW = North West, NEY = North East and Yorkshire, MID = Midlands, EE = East of England, LON = London, SW = South West, SE = South East. N.B. when the prior is region specific the prior is shown in the same columns as the posterior distributions 701

Parameter	Description	Value	Source
p _c	Probability of developing symptoms after becoming infectious	0.6	Lavezzo et al. (44)
p^*	Probability of arriving at hospital with a confirmed diagnosis	0.25	NHS (45)
1/γυ	Mean time to confirmation of diagnosis within hospital (days)	2 days	CHESS (5)
p _{seropos}	Probability of seroconversion	0.85	Brazeau et al. (42)
$1/\gamma_{sero_{pos}}$	Mean time to seroconversion from infectiousness (days)	13	Benny et al. (17)
p _{serospec}	Specificity of serology test	0.99	Brazeau et al. (42)
p _{serosens}	Sensitivity of serology test	1	Assumption as non- distinguishable from time varying seroconversion

Table S 7: Fixed model parameters (age / care home scaling factors are shown separately in Table S 8).

	Age / care home -stratified scaling to probability of:					
	Hospitalisation if symptomatic (p_H)	Triage to ICU (p _{ICU})	Death for general inpatients (p_{H_D})	Death in ICU (p _{ICUD})	Death in stepdown (p_{W_D})	Death in the community (p_{G_D})
Population group	ψ^i_H	$\psi^i_{{\scriptscriptstyle I}{\scriptscriptstyle C}{\scriptscriptstyle U}}$	$\psi^i_{\scriptscriptstyle H_D}$	$\psi^i_{{\scriptscriptstyle I}{\scriptscriptstyle C}{\scriptscriptstyle U}_D}$	$\psi^i_{{}_{W_D}}$	$\psi^i_{{}_{G_D}}$
Age						
[0, 5)	0.039	0.243	0.039	0.282	0.091	0
[5, 10)	0.001	0.289	0.037	0.286	0.083	0
[10, 15)	0.006	0.338	0.035	0.291	0.077	0
[15, 20)	0.009	0.389	0.035	0.299	0.074	0
[20, 25)	0.026	0.443	0.036	0.310	0.074	0
[25, 30)	0.040	0.503	0.039	0.328	0.076	0
[30, 35)	0.042	0.570	0.045	0.353	0.080	0
[35, 40)	0.045	0.653	0.055	0.390	0.086	0
[40, 45)	0.050	0.756	0.074	0.446	0.093	0
[45, 50)	0.074	0.866	0.107	0.520	0.102	0
[50, 55)	0.138	0.954	0.157	0.604	0.117	0
[55, 60)	0.198	1.000	0.238	0.705	0.148	0
[60, 65)	0.247	0.972	0.353	0.806	0.211	0
[65, 70)	0.414	0.854	0.502	0.899	0.332	0
[70, 75)	0.638	0.645	0.675	0.969	0.526	0
[75, 80)	1.000	0.402	0.832	1.000	0.753	0
80+	0.873	0.107	1.000	0.918	1.000	0
Care home						
CHW	0.104	0.784	0.134	0.519	0.114	0
CHR	0.873	0.107	1.000	0.918	1.000	1

707 Table S 8: Age / care-home scaling factors

Supplementary Results

2.1 Model fitting





Figure S 6: Model fits by region to PCR positivity for individuals aged >25 years (top row) and PCR positivity from the REACT-1 study (bottom row). The points show the data and bars the 95% CI. The

solid line the median model fit and the shaded area the 95% Crl.



Figure S 7: Model fits to daily hospital deaths (top row), daily care home deaths (second row), ICU bed occupancy (third row), general bed occupancy (fourth row), all hospital beds (fifth row), and all daily admissions (bottom row) by region (columns). The points show the data, the solid line the median model fit and the shaded area the 95% Crl.

723 2.2 Severity estimates



724

Figure S 8: Fits to CHESS data broken down into one-year age bands. Blue ribbons show the 95% CrI of the fitted spline, black circles and vertical segments give the raw mean and 95% CI from the data (exact binomial).

728 729

Table S 9: Age-stratified estimates of disease severity (*to 2sf, ^to 3dp)

	Age stratified estimate of:	
Age group	Proportion of infections who were hospitalised*	Proportion of infections who died^
[0, 5)	3.0% (2.8%, 3.2%)	0.031% (0.027%, 0.034%)
[5, 10)	0.26% (0.24%, 0.28%)	0.003% (0.002%, 0.003%)
[10, 15)	0.084% (0.078%, 0.089%)	0.001% (0.001%, 0.001%)
[15, 20)	0.042% (0.039%, 0.045%)	0.000% (0.000%, 0.001%)
[20, 25)	0.080% (0.075%, 0.085%)	0.001% (0.001%, 0.001%)
[25, 30)	0.26% (0.24%, 0.28%)	0.004% (0.003%, 0.004%)
[30, 35)	0.40% (0.37%, 0.42%)	0.006% (0.006%, 0.007%)
[35, 40)	0.63% (0.58%, 0.67%)	0.013% (0.011%, 0.014%)
[40, 45)	1.2% (1.1%, 1.2%)	0.031% (0.026%, 0.035%)
[45, 50)	1.9% (1.8%, 2.1%)	0.070% (0.061%, 0.080%)
[50, 55)	2.3% (2.2%, 2.5%)	0.116% (0.101%, 0.133%)
[55, 60)	4.0% (3.8%, 4.3%)	0.276% (0.242%, 0.315%)
[60, 65)	9.6% (8.9%, 10%)	0.867% (0.762%, 0.971%)
[65, 70)	10% (9.6%, 11%)	1.215% (1.070%, 1.352%)
[70, 75)	24% (22%, 26 %)	3.512% (3.083%, 3.900%)
[75, 80)	50% (46%, 53%)	8.430% (7.407%, 9.338%)
80+	50% (47%, 54%)	9.696% (8.501%, 10.640%)
Combined	20% (13%, 27%)	34.132% (28.020%, 41.359%)

Supplementary counterfactual analysis



732

Figure S 9: Counterfactual intervention scenarios in each England NHS Region: Panel A1-7 impact of
 locking down one-week earlier Panel B1-7 impact of locking down one week later; Panel C1-7 impact
 of relaxing lockdown restrictions two weeks earlier. Panel D1-7 impact of relaxing lockdown

restrictions two weeks later; Panel E1-7 impact of 50% less contact between care home residents and

the general population; Panel F1-7 impact of 50% more contact between care home residents and the
 general population.

739

740 **References**

- Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al.
 Occurrence and transmission potential of asymptomatic and presymptomatic SARS CoV-2 infections: A living systematic review and meta-analysis. PLoS Med.
 2020;17(9):e1003346.
- 745 2. GOV.UK. Coronavirus (COVID-19) in the UK [Internet]. 2020 [cited 2020 Dec 3].
 746 Available from: https://coronavirus.data.gov.uk/details/download
- Riley S, Walters CE, Wang H, Eales O, Ainslie KEC, Atchison C, et al. REACT-1
 round 7 updated report: regional heterogeneity in changes in prevalence of SARS CoV-2 infection during the second national COVID-19 lockdown in England. medRxiv.
 2020 Dec 16;2020.12.15.20248244.
- Public Health England. Sero-surveillance of COVID-19 GOV.UK [Internet]. [cited
 2020 Dec 16]. Available from: https://www.gov.uk/government/publications/nationalcovid-19-surveillance-reports/sero-surveillance-of-covid-19
- 7545.NHS Digital. SGSS and CHESS data NHS Digital [Internet]. [cited 2020 Dec 4].755Available from: https://digital.nhs.uk/about-nhs-digital/corporate-information-and-756documents/directions-and-data-provision-notices/data-provision-notices-dpns/sgss-757and-chess-data
- 6. Office for National Statistics. Office for National Statistics [Internet]. [cited 2020 Dec
 16]. Available from: https://www.ons.gov.uk/
- 760 7. Care Quality Commission. [ARCHIVED CONTENT] UK Government Web Archive 761 The National Archives [Internet]. [cited 2020 Dec 16]. Available from:
 762 https://webarchive.nationalarchives.gov.uk/20200605160439/https://www.cqc.org.uk/fi
 763 les/cqc-care-directory-filters-1-june-2020
- 764 8. GOV.UK. Care Homes Analysis Background. 2020.
- Age UK. Later Life in the United Kingdom 2019 [Internet]. [cited 2020 Dec 16].
 Available from: https://www.ageuk.org.uk/globalassets/age-uk/documents/reportsand-publications/later_life_uk_factsheet.pdf
- Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):381–91.
- 11. Ladhani SN, Chow JY, Janarthanan R, Fok J, Crawley-Boevey E, Vusirikala A, et al.
 Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020.
 EClinicalMedicine. 2020 Sep 1;26:100533.
- Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med. 2020;172(9):577–82.
- Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;(PG-).
- 14. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al.
 Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO
 Clinical Characterisation Protocol: Prospective observational cohort study. BMJ.
 2020;369(March):1–12.
- 78415.Bernabeu-Wittel M, Ternero-Vega JE, Díaz-Jiménez P, Conde-Guzmán C, Nieto-785Martín MD, Moreno-Gaviño L, et al. Death risk stratification in elderly patients with

786 787		covid-19. A comparative cohort study in nursing homes outbreaks. Arch Gerontol Geriatr. 2020;91:104240.
788 789 790 791	16.	Omar S, Bartz C, Becker S, Basenach S, Pfeifer S, Trapp C, et al. Duration of SARS-CoV-2 RNA detection in COVID-19 patients in home isolation, Rhineland-Palatinate, Germany, 2020 - an interval-censored survival analysis. Eurosurveillance. 2020;25(30):1–8.
792 793	17.	Benny B, Amandine G, Kc P, Sarah H, Abby M, Caitlin C, et al. Quantifying antibody kinetics and RNA shedding during early-phase SARS-CoV-2 infection.
794 795	18.	Funk S. Socialmixr: Social Mixing Matrices for Infectious Disease Modelling. The Comprehensive R Archive Network; 2018.
796 797 798 799	19.	GOV.UK. Prime Minister's statement on coronavirus (COVID-19): 12 March 2020 - GOV.UK [Internet]. [cited 2020 Dec 3]. Available from: https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-12-march- 2020
800 801 802 803	20.	GOV.UK. Prime Minister's statement on coronavirus (COVID-19): 22 March 2020 - GOV.UK [Internet]. [cited 2020 Dec 3]. Available from: https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-22-march- 2020
804 805 806 807	21.	GOV.UK. Prime Minister's statement on coronavirus (COVID-19): 25 March 2020 - GOV.UK [Internet]. [cited 2020 Dec 16]. Available from: https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-25-march- 2020
808 809 810	22.	GOV.UK. Prime Minister's statement on coronavirus (COVID-19): 11 May 2020 - GOV.UK [Internet]. [cited 2020 Dec 16]. Available from: https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-11-may-2020
811 812 813 814	23.	GOV.UK. Prime Minister sets out timeline for retail to reopen in June - GOV.UK [Internet]. [cited 2020 Dec 16]. Available from: https://www.gov.uk/government/news/prime-minister-sets-out-timeline-for-retail-to- reopen-in-june
815 816 817 818	24.	GOV.UK. Pubs, restaurants and hairdressers to reopen from 4 July - GOV.UK [Internet]. [cited 2020 Dec 16]. Available from: https://www.gov.uk/government/news/pubs-restaurants-and-hairdressers-to-reopen- from-4-july
819 820 821 822	25.	GOV.UK. Eat Out to Help Out launches today – with government paying half on restaurant bills - GOV.UK [Internet]. [cited 2020 Dec 16]. Available from: https://www.gov.uk/government/news/eat-out-to-help-out-launches-today-with-government-paying-half-on-restaurant-bills
823 824 825	26.	GOV.UK. Schools and colleges to reopen in full in September - GOV.UK [Internet]. [cited 2020 Dec 16]. Available from: https://www.gov.uk/government/news/schools- and-colleges-to-reopen-in-full-in-september
826 827 828	27.	GOV.UK. Rule of six comes into effect to tackle coronavirus - GOV.UK [Internet]. [cited 2020 Dec 7]. Available from: https://www.gov.uk/government/news/rule-of-six- comes-into-effect-to-tackle-coronavirus
829 830 831 832	28.	GOV.UK. Prime Minister announces new local COVID Alert Levels - GOV.UK [Internet]. [cited 2020 Dec 7]. Available from: https://www.gov.uk/government/news/prime-minister-announces-new-local-covid- alert-levels

- 833 29. GOV.UK. Prime Minister announces new national restrictions GOV.UK [Internet].
 834 [cited 2020 Dec 7]. Available from: https://www.gov.uk/government/news/prime835 minister-announces-new-national-restrictions
- 836 30. Funk S. socialmixr @ github.com.
- The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with
 Covid-19 Preliminary Report. N Engl J Med. 2020;1–11.
- Biggin 32. Diekmann O, Heesterbeek JAP, Metz JAJ. On the definition and the computation of
 the basic reproduction ratio R0 in models for infectious diseases in heterogeneous
 populations. J Math Biol. 1990;28(4):365–82.
- 842 33. Gillespie DT. Approximate accelerated stochastic simulation of chemically reacting
 843 systems. J Chem Phys. 2001;115(4):1716–33.
- 844 34. Department of Health and Social Care. COVID-19 testing data: methodology note.
 845 www.gov.uk. 2020.
- 846 35. Martin IMC, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Rapid Sequence-Based
 847 Identification of Gonococcal Transmission Clusters in a Large Metropolitan Area. J
 848 Infect Dis. 2004;189(8):1497–505.
- Bel Moral P, Doucet A, Jasra A. Sequential Monte Carlo samplers. J R Stat Soc Ser B
 Stat Methodol. 2006;68(3):411–36.
- 37. Andrieu C, Doucet A, Holenstein R. Particle Markov chain Monte Carlo methods. J R
 Stat Soc Ser B Stat Methodol. 2010;72(3):269–342.
- 38. Gordon NJ, Salmond DJ, Smith AFM. Novel approach to nonlinear/non-gaussian
 Bayesian state estimation. IEE Proceedings, Part F Radar Signal Process.
 1993;140(2):107–13.
- 856 39. Baguelin M, Knock E, Whittles LK, FitzJohn R, Lees J. sircovid. 2020.
- Knock ES, Whittles LK, Perez-Guzman PN, Bhatia S, Guntoro F, Watson OJ, et al.
 Reproducible parallel inference and simulation of stochastic state space models using odin, dust, and mcstate. Wellcome Open Res. 2020 Dec 11;5:288.
- 41. Verity R, FitzJohn R. mrc-ide/markovid at version1.5 [Internet]. [cited 2020 Dec 4].
 Available from: https://github.com/mrc-ide/markovid/tree/version1.5
- Brazeau NF, Verity R, Jenks S, Fu H, Whittaker C, Winskill P, et al. Infection Fatality
 Ratio: Estimates from Seroprevalence.
- 43. Jarvis CI, Van Zandvoort K, Gimma A, Prem K, Auzenbergs M, O'Reilly K, et al.
 Quantifying the impact of physical distance measures on the transmission of COVID19 in the UK. BMC Med. 2020;18(1):1–10.
- 44. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio
 C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'.
 Nature. 2020;
- 870 45. NHS England and NHS Improvement. Statistics » COVID-19 Hospital Activity
 871 [Internet]. [cited 2020 Dec 17]. Available from:
- 872 https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/